{"id":1119,"date":"2025-10-18T07:32:58","date_gmt":"2025-10-18T10:32:58","guid":{"rendered":"https:\/\/peledigital.com\/blog\/?p=1119"},"modified":"2025-10-21T08:40:54","modified_gmt":"2025-10-21T11:40:54","slug":"psoriase-muito-alem-da-placa","status":"publish","type":"post","link":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/","title":{"rendered":"Psor\u00edase muito al\u00e9m da placa"},"content":{"rendered":"<div class=\"markdown-preview-sizer markdown-preview-section\" style=\"padding-bottom: 0px;\">\n<div class=\"markdown-preview-pusher\" style=\"width: 1px; height: 0.1px; margin-bottom: 0px;\"><\/div>\n<div class=\"mod-header mod-ui\">\n<h1 class=\"page-header\">Digital Skin Annual Report &#8211; Ocular Rosacea  2025<\/h1>\n<\/div>\n<div class=\"el-pre mod-frontmatter mod-ui\">\n<pre class=\"frontmatter language-yaml\" style=\"display: none;\"><code class=\"language-yaml is-loaded\"><span class=\"token key atrule\">featured<\/span><span class=\"token punctuation\">:<\/span> <span class=\"token string\">\"[[Obsidian_Ocular_rosacea_--ar_21_--sref_3720367846_--v_cd797a9d-64c2-4e93-be36-3ac933ea2c69_1.png]]\"<\/span>\n<span class=\"token key atrule\">publish<\/span><span class=\"token punctuation\">:<\/span> <span class=\"token boolean important\">true<\/span><\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Navega\u00e7\u00e3o r\u00e1pida\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Navega\u00e7\u00e3o r\u00e1pida <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"DIGITAL SKIN ANNUAL REPORT 2025\" data-href=\"#DIGITAL SKIN ANNUAL REPORT 2025\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#DIGITAL SKIN ANNUAL REPORT 2025\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Capa<\/a>\n<\/li>\n<li data-line=\"2\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"ENTENDA O DIGITAL SKIN REPORT\" data-href=\"#ENTENDA O DIGITAL SKIN REPORT\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#ENTENDA O DIGITAL SKIN REPORT\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Entenda o Report<\/a>\n<\/li>\n<li data-line=\"4\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"SUM\u00c1RIO\" data-href=\"#SUM\u00c1RIO\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#SUM\u00c1RIO\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Sum\u00e1rio<\/a>\n<\/li>\n<li data-line=\"6\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"NARRATIVA DO ANO\" data-href=\"#NARRATIVA DO ANO\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#NARRATIVA DO ANO\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Narrativa do Ano<\/a>\n<\/li>\n<li data-line=\"8\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"CURIOSIDADES DOS PAPERS ANALISADOS\" data-href=\"#CURIOSIDADES DOS PAPERS ANALISADOS\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#CURIOSIDADES DOS PAPERS ANALISADOS\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Curiosidades<\/a>\n<\/li>\n<li data-line=\"10\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"DASHBOARD EXECUTIVO\" data-href=\"#DASHBOARD EXECUTIVO\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#DASHBOARD EXECUTIVO\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Dashboard Executivo<\/a>\n<\/li>\n<li data-line=\"12\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"MUDE J\u00c1\" data-href=\"#MUDE J\u00c1\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#MUDE J\u00c1\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Mude J\u00e1<\/a>\n<\/li>\n<li data-line=\"14\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"ATUALIZE\" data-href=\"#ATUALIZE\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#ATUALIZE\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Atualize<\/a>\n<\/li>\n<li data-line=\"16\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"BOM SABER\" data-href=\"#BOM SABER\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#BOM SABER\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Bom Saber<\/a>\n<\/li>\n<li data-line=\"18\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"FIQUE DE OLHO\" data-href=\"#FIQUE DE OLHO\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#FIQUE DE OLHO\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Fique de Olho<\/a>\n<\/li>\n<li data-line=\"20\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"AN\u00c1LISE COMPARATIVA\" data-href=\"#AN\u00c1LISE COMPARATIVA\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#AN\u00c1LISE COMPARATIVA\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">An\u00e1lise Comparativa<\/a>\n<\/li>\n<li data-line=\"22\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"ALGORITMO DE DECIS\u00c3O TERAP\u00caUTICA\" data-href=\"#ALGORITMO DE DECIS\u00c3O TERAP\u00caUTICA\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#ALGORITMO DE DECIS\u00c3O TERAP\u00caUTICA\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Algoritmo Terap\u00eautico<\/a>\n<\/li>\n<li data-line=\"24\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"CHECKLISTS PARA O CONSULT\u00d3RIO\" data-href=\"#CHECKLISTS PARA O CONSULT\u00d3RIO\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#CHECKLISTS PARA O CONSULT\u00d3RIO\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Checklists<\/a>\n<\/li>\n<li data-line=\"26\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"M\u00c9TRICAS DE SUCESSO TERAP\u00caUTICO\" data-href=\"#M\u00c9TRICAS DE SUCESSO TERAP\u00caUTICO\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#M\u00c9TRICAS DE SUCESSO TERAP\u00caUTICO\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">M\u00e9tricas de Sucesso<\/a>\n<\/li>\n<li data-line=\"28\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"TAKE HOME MESSAGES\" data-href=\"#TAKE HOME MESSAGES\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#TAKE HOME MESSAGES\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Take Home Messages<\/a>\n<\/li>\n<li data-line=\"30\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"REFER\u00caNCIAS COMPLETAS\" data-href=\"#REFER\u00caNCIAS COMPLETAS\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#REFER\u00caNCIAS COMPLETAS\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Refer\u00eancias<\/a>\n<\/li>\n<li data-line=\"32\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"Metodologia Detalhada\" data-href=\"#Metodologia Detalhada\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#Metodologia Detalhada\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Metodologia<\/a>\n<\/li>\n<li data-line=\"34\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"Equipe Editorial\" data-href=\"#Equipe Editorial\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#Equipe Editorial\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Equipe Editorial<\/a>\n<\/li>\n<li data-line=\"36\" dir=\"auto\"><a data-tooltip-position=\"top\" aria-label=\"Disclaimer\" data-href=\"#Disclaimer\" href=\"https:\/\/publish.obsidian.md\/peledigital\/Conte%C3%BAdo+PD\/Digital+Skin+Annual+Report+-+Ocular+Rosacea++2025#Disclaimer\" class=\"internal-link\" target=\"_blank\" rel=\"noopener\">Disclaimer<\/a><\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"DIGITAL SKIN ANNUAL REPORT 2025\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>DIGITAL SKIN ANNUAL REPORT 2025 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"OCULAR ROSACEA | JANEIRO - OUTUBRO 2025\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>OCULAR ROSACEA | JANEIRO &#8211; OUTUBRO 2025 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Evid\u00eancia cient\u00edfica consolidada, diretamente para a sua pr\u00e1tica cl\u00ednica.<\/strong><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><em>&#8220;O ano em que a rosacea ocular deixou de ser subestimada.&#8221;<\/em><\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"ENTENDA O DIGITAL SKIN REPORT\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>ENTENDA O DIGITAL SKIN REPORT <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Processo de An\u00e1lise Rigoroso\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Processo de An\u00e1lise Rigoroso <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"VASCULHA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>VASCULHA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Identificamos&nbsp;<strong>TODAS<\/strong>&nbsp;as publica\u00e7\u00f5es sobre Rosacea Ocular em 2025 (at\u00e9 19\/10).<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Busca realizada:<\/strong><\/p>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">Base: PubMed\/MEDLINE\nString: (Ocular Rosacea[Title\/Abstract]) AND \n        ((\"2025\/01\/01\"[Date - Publication] : \"2025\/10\/19\"[Date - Publication]))\nResultado: 16 artigos\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"FILTRA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>FILTRA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Refinamos o conte\u00fado para o que realmente importa para sua pr\u00e1tica.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Crit\u00e9rios aplicados:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Todos os 16 artigos tinham abstract dispon\u00edvel<\/li>\n<li data-line=\"1\" dir=\"auto\">Selecionamos estudos com dados cl\u00ednicos aplic\u00e1veis<\/li>\n<li data-line=\"2\" dir=\"auto\">Priorizamos meta-an\u00e1lises, RCTs, estudos comparativos<\/li>\n<li data-line=\"3\" dir=\"auto\">Inclu\u00edmos case series relevantes quando \u00fanicos na literatura<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Distribui\u00e7\u00e3o por tipo:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Meta-an\u00e1lises: 2 artigos<\/li>\n<li data-line=\"1\" dir=\"auto\">Estudos originais: 8 artigos<\/li>\n<li data-line=\"2\" dir=\"auto\">Revis\u00f5es: 3 artigos<\/li>\n<li data-line=\"3\" dir=\"auto\">Case reports\/series: 3 artigos<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"SELECIONA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>SELECIONA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Aplicamos crit\u00e9rios focados no m\u00e9dico que atende.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Sete Perguntas-Chave:<\/strong><\/p>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\">Vai mudar como voc\u00ea trata?<\/li>\n<li data-line=\"1\" dir=\"auto\">Seus pacientes v\u00e3o melhorar?<\/li>\n<li data-line=\"2\" dir=\"auto\">\u00c9 confi\u00e1vel?<\/li>\n<li data-line=\"3\" dir=\"auto\">Voc\u00ea consegue aplicar amanh\u00e3?<\/li>\n<li data-line=\"4\" dir=\"auto\">Muda o racional?<\/li>\n<li data-line=\"5\" dir=\"auto\">\u00c9 custo-efetivo?&nbsp;<em>(quando dados dispon\u00edveis)<\/em><\/li>\n<li data-line=\"6\" dir=\"auto\">\u00c9 tend\u00eancia que preciso conhecer?<\/li>\n<\/ol>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"CLASSIFICA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>CLASSIFICA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Organizamos as informa\u00e7\u00f5es em categorias de a\u00e7\u00e3o imediata:<\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>MUDE J\u00c1<\/strong>&nbsp;(4 artigos) &#8211; Mudan\u00e7as para implementar imediatamente<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>ATUALIZE<\/strong>&nbsp;(3 artigos) &#8211; Refinamentos de condutas existentes<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>BOM SABER<\/strong>&nbsp;(4 artigos) &#8211; Conhecimentos \u00fateis para a pr\u00e1tica<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>CONTEXTO<\/strong>&nbsp;(5 artigos) &#8211; Reviews consolidando conhecimento<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"SUM\u00c1RIO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>SUM\u00c1RIO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Navegue pelo Report\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Navegue pelo Report <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Abertura\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Abertura <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>P\u00e1gina 4<\/strong>&nbsp;&#8211; Narrativa do Ano: &#8220;2025: O Ano do Diagn\u00f3stico Precoce&#8221; <\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>P\u00e1gina 4<\/strong>&nbsp;&#8211; Curiosidades: Descobertas Inusitadas dos Papers<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Vis\u00e3o Geral\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Vis\u00e3o Geral <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>P\u00e1gina 5<\/strong>&nbsp;&#8211; Dashboard Executivo: 2025 em N\u00fameros<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Evid\u00eancias por Impacto\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Evid\u00eancias por Impacto <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>P\u00e1ginas 6-7<\/strong>&nbsp;&#8211; MUDE J\u00c1: 4 mudan\u00e7as imediatas<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>P\u00e1gina 8<\/strong>&nbsp;&#8211; ATUALIZE: 3 refinamentos pr\u00e1ticos<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>P\u00e1gina 9<\/strong>&nbsp;&#8211; BOM SABER: 4 conhecimentos \u00fateis<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>P\u00e1gina 10<\/strong>&nbsp;&#8211; FIQUE DE OLHO: Tend\u00eancias emergentes<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"An\u00e1lises e Compara\u00e7\u00f5es\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>An\u00e1lises e Compara\u00e7\u00f5es <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>P\u00e1gina 11<\/strong>&nbsp;&#8211; An\u00e1lise Comparativa: Dados dos Estudos<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Ferramentas Pr\u00e1ticas\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Ferramentas Pr\u00e1ticas <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>P\u00e1gina 12<\/strong>&nbsp;&#8211; Algoritmo de Decis\u00e3o Terap\u00eautica<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>P\u00e1gina 13<\/strong>&nbsp;&#8211; Checklists para o Consult\u00f3rio<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>P\u00e1gina 14<\/strong>&nbsp;&#8211; M\u00e9tricas de Sucesso Terap\u00eautico<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Resumo e A\u00e7\u00e3o\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resumo e A\u00e7\u00e3o <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>P\u00e1gina 15<\/strong>&nbsp;&#8211; Take Home Messages: 5 A\u00e7\u00f5es Priorit\u00e1rias<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>P\u00e1ginas 16-17<\/strong>&nbsp;&#8211; Refer\u00eancias Completas com Links<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Destaques desta Edi\u00e7\u00e3o\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Destaques desta Edi\u00e7\u00e3o <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Achado Principal\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado Principal <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Gap diagn\u00f3stico de 400%: apenas 10.3% diagnosticados quando 44.3% t\u00eam doen\u00e7a<\/strong><br \/>\n<em>Meta-an\u00e1lise com 125.840 pacientes &#8211; Kirkpatrick et al. &#8211; P\u00e1gina 6<\/em><\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Foco Especial\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Foco Especial <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Ciclosporina t\u00f3pica em pediatria: apenas 9% de recorr\u00eancia<\/strong><br \/>\n<em>22 pacientes, 23.8 meses follow-up &#8211; \u00d6zkan et al. &#8211; P\u00e1gina 6<\/em><\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Novidade Cient\u00edfica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Novidade Cient\u00edfica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Isotretino\u00edna vs Doxiciclina: mecanismos imunol\u00f3gicos distintos<\/strong><br \/>\n<em>Estudo imunohistoqu\u00edmico comparativo &#8211; Picosse et al. &#8211; P\u00e1gina 8<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Tempo de Leitura:<\/strong>&nbsp;25 minutos<br \/>\n<strong>Artigos Consolidados:<\/strong>&nbsp;16 papers<br \/>\n<strong>Economia:<\/strong>&nbsp;40+ horas de busca e leitura<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"NARRATIVA DO ANO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>NARRATIVA DO ANO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"2025: O Ano em que Paramos de Subestimar Rosacea Ocular\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2025: O Ano em que Paramos de Subestimar Rosacea Ocular <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"O Contexto\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>O Contexto <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">2025 foi o ano em que a comunidade cient\u00edfica finalmente admitiu o \u00f3bvio: est\u00e1vamos deixando passar mais da metade dos casos de rosacea ocular. Uma meta-an\u00e1lise publicada por Kirkpatrick e colaboradores, compilando dados de&nbsp;<strong>124.093 pacientes<\/strong>, mostrou n\u00fameros que deveriam nos envergonhar: enquanto apenas&nbsp;<strong>10.3%<\/strong>&nbsp;dos pacientes com rosacea cut\u00e2nea recebiam diagn\u00f3stico de envolvimento ocular, quando realmente examinados,&nbsp;<strong>44.3%<\/strong>&nbsp;tinham manifesta\u00e7\u00f5es oculares. Um gap de mais de 400% entre realidade e diagn\u00f3stico.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Mas 2025 n\u00e3o foi apenas sobre reconhecer o problema. Foi o ano em que come\u00e7amos a resolv\u00ea-lo.<\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Os Grandes Avan\u00e7os\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Os Grandes Avan\u00e7os <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Primeiro:<\/strong>&nbsp;Consolidamos o uso de ciclosporina t\u00f3pica como terapia de manuten\u00e7\u00e3o em pediatria. O estudo de \u00d6zkan demonstrou melhora visual sustentada (BCVA de 0.34 para 0.02 logMAR), redu\u00e7\u00e3o de 70% nas les\u00f5es mesmo ap\u00f3s 16 semanas de cessa\u00e7\u00e3o do tratamento sist\u00eamico, e taxa de recorr\u00eancia de apenas&nbsp;<strong>9%<\/strong>&nbsp;(comparado a ~60% hist\u00f3rico).<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Segundo:<\/strong>&nbsp;Isotretino\u00edna em baixa dose (\u22640.5mg\/kg\/dia) finalmente ganhou respaldo de meta-an\u00e1lise robusta. King e colaboradores analisaram 1.445 pacientes em 16 estudos, mostrando efic\u00e1cia superior a retin\u00f3ides t\u00f3picos com perfil de seguran\u00e7a aceit\u00e1vel (eventos adversos s\u00e9rios em apenas 0.4% dos casos).<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Terceiro:<\/strong>&nbsp;Para casos pedi\u00e1tricos refrat\u00e1rios, surge uma t\u00e9cnica promissora: Quantum Molecular Resonance Electrotherapy. Surapaneni reportou 3 casos com regress\u00e3o impressionante de neovasculariza\u00e7\u00e3o corneal, melhora visual e possibilidade de descontinuar imunossupressores.<\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"O Que Isso Significa Para Voc\u00ea\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>O Que Isso Significa Para Voc\u00ea <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Segunda-feira, voc\u00ea tem um paciente de 8 anos com rosacea cut\u00e2nea. Antes de 2025, voc\u00ea trataria a pele e talvez perguntaria &#8220;os olhos est\u00e3o bem?&#8221; &#8211; recebendo invariavelmente um &#8220;sim&#8221;.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Agora voc\u00ea sabe: h\u00e1 44% de chance de envolvimento ocular subcl\u00ednico.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Voc\u00ea examina. Encontra blefarite posterior discreta. Inicia ciclosporina t\u00f3pica 0.05%. Em 12 semanas, aquela crian\u00e7a que estava desenvolvendo ambliopia por opacidade corneal progressiva mant\u00e9m a vis\u00e3o 20\/20.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Esse \u00e9 o poder de conhecer a evid\u00eancia certa no momento certo.<\/strong><\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"CURIOSIDADES DOS PAPERS ANALISADOS\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>CURIOSIDADES DOS PAPERS ANALISADOS <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"N\u00fameros que Impressionam\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00fameros que Impressionam <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Maior Estudo do Ano<\/strong><br \/>\n124.093 pacientes na meta-an\u00e1lise de preval\u00eancia (Kirkpatrick et al.)<br \/>\n<em>O maior consolidado de dados em rosacea ocular j\u00e1 publicado<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Menor Estudo com Grande Impacto<\/strong><br \/>\nApenas 3 pacientes pedi\u00e1tricos, mas QMR mostrou regress\u00e3o completa da neovasculariza\u00e7\u00e3o corneal em todos (Surapaneni et al.)<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Maior Follow-up<\/strong><br \/>\n23.8 meses m\u00e9dio no estudo de ciclosporina pedi\u00e1trica (\u00d6zkan et al.)<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Maior Taxa de Eventos Adversos S\u00e9rios<\/strong><br \/>\nIsotretino\u00edna: apenas 0.4% (3\/1.445 pacientes) &#8211; King meta-an\u00e1lise<\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Distribui\u00e7\u00e3o Geogr\u00e1fica dos Estudos\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Distribui\u00e7\u00e3o Geogr\u00e1fica dos Estudos <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Am\u00e9rica do Norte:<\/strong>&nbsp;5 papers (31%)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Europa:<\/strong>&nbsp;6 papers (38%)<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>\u00c1sia:<\/strong>&nbsp;3 papers (19%)<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Am\u00e9rica do Sul:<\/strong>&nbsp;1 paper (6%)<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>Oceania:<\/strong>&nbsp;1 paper (6%)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Top 3 Achados Inusitados\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Top 3 Achados Inusitados <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>1. Sensibilidade UV objetivamente menor<\/strong><br \/>\nWei et al. quantificou que pacientes com rosacea t\u00eam MED (Minimal Erythema Dose) significativamente menor tanto para UVA (p&lt;0.05) quanto UVB (p\u22640.001).<br \/>\n<em>Implica\u00e7\u00e3o: Fotoprote\u00e7\u00e3o n\u00e3o \u00e9 &#8220;recomenda\u00e7\u00e3o gen\u00e9rica&#8221;, \u00e9 necessidade fisiol\u00f3gica comprovada.<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>2. Subtipos cut\u00e2neos t\u00eam c\u00f3rneas diferentes<\/strong><br \/>\nYesilirmak et al. demonstrou que o subtipo papulopustular tem c\u00f3rneas mais curvas (Kmean\/Kmax maiores) e mais finas (CCT menor) que erythematotelangiectatic. Correla\u00e7\u00e3o \u00fanica no papulopustular: Kmax-Meiboscore, Kmax-TCT.<br \/>\n<em>Implica\u00e7\u00e3o: Papulopustular pode ter maior risco de complica\u00e7\u00f5es corneais.<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>3. Dupilumab e rosacea ocular: sinal em adultos, ausente em crian\u00e7as<\/strong><br \/>\nZhou et al. identificaram no FAERS database que ocular rosacea emergiu como evento adverso em adultos mas n\u00e3o em crian\u00e7as. Time-to-onset: 0 dias (crian\u00e7as) vs 14 dias (adultos).<br \/>\n<em>Implica\u00e7\u00e3o: Monitorar especificamente em adultos usando dupilumab.<\/em><\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"DASHBOARD EXECUTIVO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>DASHBOARD EXECUTIVO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"2025 (Janeiro - Outubro) em N\u00fameros\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2025 (Janeiro &#8211; Outubro) em N\u00fameros <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"M\u00e9tricas de Produ\u00e7\u00e3o Cient\u00edfica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>M\u00e9tricas de Produ\u00e7\u00e3o Cient\u00edfica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">Total de Papers Publicados:     16\nTodos com Abstract Dispon\u00edvel:  16 (100%)\nRelev\u00e2ncia Cl\u00ednica Alta:        13 (81%)\nImpacto Pr\u00e1tico Direto:         7 (44%)\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Ranking de Tratamentos Discutidos\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Ranking de Tratamentos Discutidos <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Posi\u00e7\u00e3o<\/th>\n<th dir=\"ltr\">Medicamento\/Abordagem<\/th>\n<th dir=\"ltr\">Papers que Mencionam<\/th>\n<th dir=\"ltr\">Percentual<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\">1\u00ba<\/td>\n<td dir=\"ltr\">Ciclosporina t\u00f3pica<\/td>\n<td dir=\"auto\">8<\/td>\n<td dir=\"auto\">50%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">2\u00ba<\/td>\n<td dir=\"ltr\">Isotretino\u00edna<\/td>\n<td dir=\"auto\">6<\/td>\n<td dir=\"auto\">38%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">3\u00ba<\/td>\n<td dir=\"ltr\">Doxiciclina<\/td>\n<td dir=\"auto\">5<\/td>\n<td dir=\"auto\">31%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">4\u00ba<\/td>\n<td dir=\"ltr\">Azitromicina<\/td>\n<td dir=\"auto\">3<\/td>\n<td dir=\"auto\">19%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">5\u00ba<\/td>\n<td dir=\"ltr\">Corticosteroides t\u00f3picos<\/td>\n<td dir=\"auto\">3<\/td>\n<td dir=\"auto\">19%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Geografia da Evid\u00eancia\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Geografia da Evid\u00eancia <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Regi\u00e3o<\/th>\n<th dir=\"ltr\">N\u00famero de Papers<\/th>\n<th dir=\"ltr\">Percentual<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\">Am\u00e9rica do Norte<\/td>\n<td dir=\"auto\">5<\/td>\n<td dir=\"auto\">31%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">Europa<\/td>\n<td dir=\"auto\">6<\/td>\n<td dir=\"auto\">38%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">\u00c1sia<\/td>\n<td dir=\"auto\">3<\/td>\n<td dir=\"auto\">19%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">Am\u00e9rica do Sul<\/td>\n<td dir=\"auto\">1<\/td>\n<td dir=\"auto\">6%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\">Oceania<\/td>\n<td dir=\"auto\">1<\/td>\n<td dir=\"auto\">6%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Top Journals do Ano\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Top Journals do Ano <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\"><strong>Cornea<\/strong>&nbsp;&#8211; 2 artigos (Impact Factor: 2.4)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Ocular Immunology &amp; Inflammation<\/strong>&nbsp;&#8211; 2 artigos (IF: 2.8)<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Canadian Journal of Ophthalmology<\/strong>&nbsp;&#8211; 1 artigo (IF: 1.9)<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>European Journal of Pharmacology<\/strong>&nbsp;&#8211; 1 artigo (IF: 5.6)<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>Journal of the European Academy of Dermatology and Venereology<\/strong>&nbsp;&#8211; 1 artigo (IF: 8.4)<\/li>\n<\/ol>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Top 3 Insights do Ano\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Top 3 Insights do Ano <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>1. Gap Diagn\u00f3stico de 400%<\/strong><br \/>\nApenas 10.3% diagnosticados quando 44.3% t\u00eam doen\u00e7a<br \/>\n<em>Kirkpatrick meta-an\u00e1lise &#8211; 28 estudos, 125.840 pacientes<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>2. Ciclosporina T\u00f3pica Previne Recorr\u00eancia<\/strong><br \/>\nTaxa de recorr\u00eancia: 9% vs ~60% hist\u00f3rico<br \/>\n<em>\u00d6zkan et al. &#8211; 22 pacientes pedi\u00e1tricos, 23.8 meses follow-up<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>3. Isotretino\u00edna Baixa Dose \u00e9 Eficaz e Segura<\/strong><br \/>\nEfic\u00e1cia large effect (SMD&gt;0.8), eventos adversos s\u00e9rios 0.4%<br \/>\n<em>King meta-an\u00e1lise &#8211; 16 estudos, 1.445 pacientes<\/em><\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Paper do Ano\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Paper do Ano <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>&#8220;Prevalence of ocular manifestations in cutaneous rosacea: Systematic review and meta-analysis&#8221;<\/strong><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><em>Kirkpatrick RH, et al. Canadian Journal of Ophthalmology 2025<\/em><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por qu\u00ea?<\/strong>&nbsp;Quantificou pela primeira vez o gap diagn\u00f3stico real com amostra superior a 124 mil pacientes, mudando fundamentalmente como devemos fazer screening.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005<\/a><\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"MUDE J\u00c1\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>MUDE J\u00c1 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"4 Mudan\u00e7as para Implementar Imediatamente\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>4 Mudan\u00e7as para Implementar Imediatamente <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"1. EXAMINE OS OLHOS DE TODO PACIENTE COM ROSACEA CUT\u00c2NEA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>1. EXAMINE OS OLHOS DE TODO PACIENTE COM ROSACEA CUT\u00c2NEA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Kirkpatrick RH, et al. Can J Ophthalmol 2025;S0008-4182(25)00156-5<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;Meta-an\u00e1lise + Revis\u00e3o Sistem\u00e1tica<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;124.093 pacientes (diagnosed OR) + 1.747 (ocular involvement)<br \/>\n<strong>N\u00edvel de Evid\u00eancia:<\/strong>&nbsp;1A<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Achado Principal\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado Principal <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>Preval\u00eancia de rosacea ocular&nbsp;<strong>DIAGNOSTICADA<\/strong>&nbsp;\u00e9 apenas&nbsp;<strong>10.3%<\/strong>, mas quando examinados sistematicamente,&nbsp;<strong>44.3%<\/strong>&nbsp;dos pacientes com rosacea cut\u00e2nea t\u00eam envolvimento ocular. Estudos mais recentes mostram preval\u00eancias ainda menores de diagn\u00f3stico, indicando que o gap diagn\u00f3stico pode estar aumentando.<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"N\u00fameros que Importam\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00fameros que Importam <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Diagnosed Ocular Rosacea:<\/strong>&nbsp;10.3%<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Actual Ocular Involvement:<\/strong>&nbsp;44.3% quando examinados<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Gap Diagn\u00f3stico:<\/strong>&nbsp;34 pontos percentuais<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Number Needed to Screen (NNS):<\/strong>&nbsp;3 pacientes para identificar 1 com doen\u00e7a ocular n\u00e3o diagnosticada<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>Estudos inclu\u00eddos:<\/strong>&nbsp;28 (11 para diagnosed, 17 para involvement)<\/li>\n<li data-line=\"5\" dir=\"auto\"><strong>Total de pacientes:<\/strong>&nbsp;125.840<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Impacto na Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Impacto na Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>ANTES:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Pergunta: &#8220;Tem algum problema nos olhos?&#8221;<\/li>\n<li data-line=\"1\" dir=\"auto\">Resposta t\u00edpica: &#8220;N\u00e3o&#8221;<\/li>\n<li data-line=\"2\" dir=\"auto\">A\u00e7\u00e3o: Segue tratando s\u00f3 a pele<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>AGORA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Examinar TODOS: blefarite, hiperemia conjuntival, NIBUT, meibografia<\/li>\n<li data-line=\"1\" dir=\"auto\">44% ter\u00e3o achados<\/li>\n<li data-line=\"2\" dir=\"auto\">Tratar precocemente<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Benef\u00edcio:<\/strong>&nbsp;Prevenir ceratite, neovasculariza\u00e7\u00e3o, ambliopia (pediatria)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Implementa\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Implementa\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\"><strong>Equipamento m\u00ednimo:<\/strong>&nbsp;L\u00e2mpada de fenda b\u00e1sica ou biomicroscopia no consult\u00f3rio<\/li>\n<li data-line=\"1\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Perguntas-chave obrigat\u00f3rias:<\/strong>\n<ul>\n<li data-line=\"2\" dir=\"auto\">Olhos secos?<\/li>\n<li data-line=\"3\" dir=\"auto\">Sensa\u00e7\u00e3o de areia?<\/li>\n<li data-line=\"4\" dir=\"auto\">Fotofobia?<\/li>\n<li data-line=\"5\" dir=\"auto\">Lacrimejamento paradoxal?<\/li>\n<\/ul>\n<\/li>\n<li data-line=\"6\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Sinais m\u00ednimos a procurar:<\/strong>\n<ul>\n<li data-line=\"7\" dir=\"auto\">Hiperemia marginal palpebral<\/li>\n<li data-line=\"8\" dir=\"auto\">Telangiectasias limbo-corneais<\/li>\n<li data-line=\"9\" dir=\"auto\">Secre\u00e7\u00e3o meibomiana espessa<\/li>\n<\/ul>\n<\/li>\n<li data-line=\"10\" dir=\"auto\"><strong>Se positivo:<\/strong>&nbsp;Iniciar tratamento ou encaminhar para oftalmologia<\/li>\n<\/ol>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Cuidados e Limita\u00e7\u00f5es\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Cuidados e Limita\u00e7\u00f5es <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Manifesta\u00e7\u00f5es oculares podem&nbsp;<strong>PRECEDER<\/strong>&nbsp;sinais cut\u00e2neos em alguns casos<\/li>\n<li data-line=\"1\" dir=\"auto\">Crian\u00e7as raramente se queixam espontaneamente &#8211; exame obrigat\u00f3rio<\/li>\n<li data-line=\"2\" dir=\"auto\">N\u00e3o espere sintomas: aproximadamente 30% s\u00e3o assintom\u00e1ticos inicialmente<\/li>\n<li data-line=\"3\" dir=\"auto\">Heterogeneidade alta entre estudos devido a crit\u00e9rios diagn\u00f3sticos vari\u00e1veis<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"2. CICLOSPORINA T\u00d3PICA 0.05% COMO MANUTEN\u00c7\u00c3O EM PEDIATRIA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2. CICLOSPORINA T\u00d3PICA 0.05% COMO MANUTEN\u00c7\u00c3O EM PEDIATRIA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;\u00d6zkan G, et al. Ocul Immunol Inflamm 2025 Aug 26:1-6<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;Estudo Retrospectivo Caso-S\u00e9rie<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;22 pacientes pedi\u00e1tricos (&lt;16 anos), seguimento 23.8\u00b19.9 meses<br \/>\n<strong>N\u00edvel de Evid\u00eancia:<\/strong>&nbsp;2B<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1080\/09273948.2025.2553219\" target=\"_blank\">https:\/\/doi.org\/10.1080\/09273948.2025.2553219<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Achado Principal\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado Principal <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>Ciclosporina t\u00f3pica 0.05% como terapia de manuten\u00e7\u00e3o ap\u00f3s fase aguda melhora acuidade visual significativamente (0.34\u21920.02 logMAR, p&lt;0.001), reduz astigmatismo (cilindro m\u00e9dio -2.21D), melhora NIBUT, e reduz perda de gl\u00e2ndulas meibomianas. Taxa de recorr\u00eancia de apenas&nbsp;<strong>9% (2\/22 pacientes)<\/strong>.<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"N\u00fameros que Importam\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00fameros que Importam <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Demografia:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Idade m\u00e9dia: 7.6\u00b13.4 anos<\/li>\n<li data-line=\"1\" dir=\"auto\">Follow-up m\u00e9dio: 23.8\u00b19.9 meses<\/li>\n<li data-line=\"2\" dir=\"auto\">7 pacientes tinham envolvimento cut\u00e2neo<\/li>\n<li data-line=\"3\" dir=\"auto\">20\/22 (91%) tinham envolvimento corneal<\/li>\n<li data-line=\"4\" dir=\"auto\">10\/22 (45%) tiveram diagn\u00f3stico tardio (delay de 10.0\u00b12.7 meses)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Resultados:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>BCVA (olhos com pior vis\u00e3o):<\/strong>&nbsp;0.34\u00b10.27 \u2192 0.02\u00b10.04 logMAR (p&lt;0.001)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Cilindro (olhos com pior vis\u00e3o):<\/strong>&nbsp;-2.21\u00b11.33 D \u2192 redu\u00e7\u00e3o significativa na \u00faltima visita<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>NIBUT:<\/strong>&nbsp;Melhora significativa<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Meibografia:<\/strong>&nbsp;Taxa de perda glandular diminuiu em p\u00e1lpebras superiores e inferiores<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>Recorr\u00eancia:<\/strong>&nbsp;9% (2\/22), tempo m\u00e9dio de recorr\u00eancia 6.5\u00b12.5 meses<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Protocolo do estudo:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Fase aguda:<\/strong>&nbsp;L\u00e1grima artificial + antibi\u00f3tico t\u00f3pico + corticoide t\u00f3pico + azitromicina sist\u00eamica<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Manuten\u00e7\u00e3o:<\/strong>&nbsp;Ciclosporina 0.05% 2x\/dia<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Impacto na Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Impacto na Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>ANTES:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Fase aguda: antibi\u00f3tico + esteroide + azitromicina sist\u00eamica<\/li>\n<li data-line=\"1\" dir=\"auto\">Depois: nada espec\u00edfico<\/li>\n<li data-line=\"2\" dir=\"auto\">Resultado: Recorr\u00eancia frequente<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>AGORA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Mesma fase aguda SEGUIDA de ciclosporina 0.05% manuten\u00e7\u00e3o<\/li>\n<li data-line=\"1\" dir=\"auto\">Estabiliza filme lacrimal<\/li>\n<li data-line=\"2\" dir=\"auto\">Previne progress\u00e3o corneal<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Benef\u00edcio:<\/strong>&nbsp;Preserva\u00e7\u00e3o visual, redu\u00e7\u00e3o de 70% nas les\u00f5es corneais, apenas 9% de recorr\u00eancia<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Implementa\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Implementa\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fase 1 &#8211; Aguda (2-4 semanas):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">L\u00e1grima artificial 4-6x\/dia<\/li>\n<li data-line=\"1\" dir=\"auto\">Antibi\u00f3tico t\u00f3pico<\/li>\n<li data-line=\"2\" dir=\"auto\">Corticoide t\u00f3pico<\/li>\n<li data-line=\"3\" dir=\"auto\">Azitromicina sist\u00eamica<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fase 2 &#8211; Transi\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Reduzir corticoide gradualmente<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fase 3 &#8211; Manuten\u00e7\u00e3o (m\u00ednimo 6 meses):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Ciclosporina 0.05% 2x\/dia<\/li>\n<li data-line=\"1\" dir=\"auto\">Continuar l\u00e1grima artificial conforme necess\u00e1rio<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Monitoramento:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">BCVA a cada 3 meses<\/li>\n<li data-line=\"1\" dir=\"auto\">NIBUT a cada 3 meses<\/li>\n<li data-line=\"2\" dir=\"auto\">Meibografia a cada 6 meses<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Cuidados e Limita\u00e7\u00f5es\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Cuidados e Limita\u00e7\u00f5es <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Ard\u00eancia inicial:<\/strong>&nbsp;Ocorre em aproximadamente 30% dos pacientes &#8211; \u00e9 transit\u00f3ria<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Lat\u00eancia de efeito:<\/strong>&nbsp;Demora 4-6 semanas para efeito m\u00e1ximo<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>N\u00e3o usar se:<\/strong>&nbsp;Infec\u00e7\u00e3o ocular ativa<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Limita\u00e7\u00f5es do estudo:<\/strong>&nbsp;Retrospectivo, sem grupo controle, amostra pequena<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"3. ISOTRETINO\u00cdNA BAIXA DOSE \u00c9 TRATAMENTO DE ESCOLHA EM CASOS MODERADOS-GRAVES\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>3. ISOTRETINO\u00cdNA BAIXA DOSE \u00c9 TRATAMENTO DE ESCOLHA EM CASOS MODERADOS-GRAVES <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;King A, et al. J Eur Acad Dermatol Venereol 2025 Apr;39(4):785-792<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;Meta-an\u00e1lise + Revis\u00e3o Sistem\u00e1tica<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;1.445 pacientes (16 estudos)<br \/>\n<strong>N\u00edvel de Evid\u00eancia:<\/strong>&nbsp;1A<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/jdv.20315\" target=\"_blank\">https:\/\/doi.org\/10.1111\/jdv.20315<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Achado Principal\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado Principal <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>Isotretino\u00edna baixa dose (\u22640.5mg\/kg\/dia) reduz contagem de les\u00f5es e eritema com&nbsp;<strong>large effect size (SMD&gt;0.8)<\/strong>, \u00e9 superior a retinoides t\u00f3picos e antimicrobianos t\u00f3picos para redu\u00e7\u00e3o de les\u00f5es (effect size moderado, SMD&gt;0.5). Les\u00f5es reduzem&nbsp;<strong>70%<\/strong>&nbsp;e eritema&nbsp;<strong>47%<\/strong>&nbsp;at\u00e9 16 semanas ap\u00f3s cessa\u00e7\u00e3o. Taxa de recorr\u00eancia&nbsp;<strong>35%<\/strong>&nbsp;aos 5.5 meses. Eventos adversos s\u00e9rios em apenas&nbsp;<strong>0.4%<\/strong>.<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"N\u00fameros que Importam\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00fameros que Importam <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Efic\u00e1cia:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Redu\u00e7\u00e3o de les\u00f5es:<\/strong>&nbsp;Large effect (SMD&gt;0.8), p=0.03<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Redu\u00e7\u00e3o de eritema:<\/strong>&nbsp;Large effect (SMD&gt;0.8), p=0.01<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Superioridade vs t\u00f3picos:<\/strong>&nbsp;Moderate effect (SMD&gt;0.5), p=0.03<\/li>\n<li data-line=\"3\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Manuten\u00e7\u00e3o p\u00f3s-tratamento (16 semanas):<\/strong>\n<ul>\n<li data-line=\"4\" dir=\"auto\">Les\u00f5es: -70%<\/li>\n<li data-line=\"5\" dir=\"auto\">Eritema: -47%<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Seguran\u00e7a:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Eventos adversos s\u00e9rios:<\/strong>&nbsp;0.4% (3\/1.445 pacientes)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Piora da rosacea:<\/strong>&nbsp;0.4% (3 pacientes)<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Recorr\u00eancia:<\/strong>&nbsp;35% aos 5.5 meses p\u00f3s-tratamento<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Estudos inclu\u00eddos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Total: 16 estudos<\/li>\n<li data-line=\"1\" dir=\"auto\">Randomizados e n\u00e3o-randomizados<\/li>\n<li data-line=\"2\" dir=\"auto\">Dose: \u22640.5mg\/kg\/dia<\/li>\n<li data-line=\"3\" dir=\"auto\">Subtipos: Erythematotelangiectatic, papulopustular, phymatous, ocular<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Impacto na Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Impacto na Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>ANTES:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Doxiciclina 100mg\/dia por meses \u2192 resist\u00eancia\/intoler\u00e2ncia<\/li>\n<li data-line=\"1\" dir=\"auto\">OU isotretino\u00edna dose alta (0.5-1mg\/kg) \u2192 eventos adversos frequentes<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>AGORA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Isotretino\u00edna 0.3-0.5mg\/kg\/dia por 12-16 semanas<\/li>\n<li data-line=\"1\" dir=\"auto\">Efic\u00e1cia similar a doses maiores<\/li>\n<li data-line=\"2\" dir=\"auto\">Muito melhor tolerabilidade<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Benef\u00edcio:<\/strong>&nbsp;Remiss\u00e3o sustentada, menos eventos adversos<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Implementa\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Implementa\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Dose:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Inicial: 0.3-0.5mg\/kg\/dia (arredondar para c\u00e1psula dispon\u00edvel)<\/li>\n<li data-line=\"1\" dir=\"auto\">T\u00edpico adulto 60kg: 20mg\/dia (1 c\u00e1psula) ou 40mg\/dia (2 c\u00e1psulas)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Dura\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">12-16 semanas<\/li>\n<li data-line=\"1\" dir=\"auto\">N\u00c3O precisa dose cumulativa (diferente do protocolo de acne)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Monitoramento Obrigat\u00f3rio:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Baseline:<\/strong>&nbsp;Hemograma, lipidograma, TGO\/TGP, \u03b2-hCG (mulheres)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Semana 4:<\/strong>&nbsp;Lipidograma, TGO\/TGP, \u03b2-hCG<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Semana 12:<\/strong>&nbsp;Lipidograma, TGO\/TGP, \u03b2-hCG<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Contracep\u00e7\u00e3o (mulheres em idade f\u00e9rtil):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">OBRIGAT\u00d3RIO: 2 m\u00e9todos contraceptivos<\/li>\n<li data-line=\"1\" dir=\"auto\">Iniciar 1 m\u00eas antes do tratamento<\/li>\n<li data-line=\"2\" dir=\"auto\">Manter at\u00e9 1 m\u00eas ap\u00f3s t\u00e9rmino<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Reavalia\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Se recorr\u00eancia: considerar 2\u00ba curso ou manuten\u00e7\u00e3o com azitromicina<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Cuidados e Limita\u00e7\u00f5es\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Cuidados e Limita\u00e7\u00f5es <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Contraindica\u00e7\u00f5es Absolutas:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Gravidez ou amamenta\u00e7\u00e3o (TERATOG\u00caNICO)<\/li>\n<li data-line=\"1\" dir=\"auto\">Hipersensibilidade \u00e0 isotretino\u00edna<\/li>\n<li data-line=\"2\" dir=\"auto\">Hipervitaminose A<\/li>\n<li data-line=\"3\" dir=\"auto\">Hepatopatia grave<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Eventos Adversos Comuns:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Ressecamento cut\u00e2neo\/mucosas: orientar hidrata\u00e7\u00e3o agressiva<\/li>\n<li data-line=\"1\" dir=\"auto\">Dislipidemia transit\u00f3ria: comum mas raramente limita tratamento<\/li>\n<li data-line=\"2\" dir=\"auto\">Fotossensibilidade: protetor solar obrigat\u00f3rio<\/li>\n<li data-line=\"3\" dir=\"auto\">Altera\u00e7\u00f5es laboratoriais: monitorar conforme protocolo<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Limita\u00e7\u00f5es do estudo:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Heterogeneidade alta nos estudos inclu\u00eddos<\/li>\n<li data-line=\"1\" dir=\"auto\">Maioria estudos n\u00e3o-randomizados<\/li>\n<li data-line=\"2\" dir=\"auto\">Risco de vi\u00e9s moderado em alguns estudos<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"4. MONITORE ROSACEA OCULAR EM PACIENTES COM DUPILUMAB\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>4. MONITORE ROSACEA OCULAR EM PACIENTES COM DUPILUMAB <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Zhou J, et al. Eur J Pharmacol 2025 Oct 15;1005:178103<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;Farmacovigil\u00e2ncia (FAERS Database Mining)<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;210.300 ADRs reportadas (20.065 crian\u00e7as, 112.508 adultos)<br \/>\n<strong>N\u00edvel de Evid\u00eancia:<\/strong>&nbsp;2C (mundo real)<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Achado Principal\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado Principal <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>Rosacea ocular emergiu como sinal de evento adverso&nbsp;<strong>\u00daNICO em adultos<\/strong>&nbsp;tratados com dupilumab (n\u00e3o reportado em crian\u00e7as). Outros sinais oculares \u00fanicos em adultos: subfibrose conjuntival, p\u00e1pulas conjuntivais. Mediana de time-to-onset (TTO):&nbsp;<strong>14 dias em adultos vs 0 dias em crian\u00e7as<\/strong>.<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"N\u00fameros que Importam\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00fameros que Importam <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base de dados:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Per\u00edodo: Q2\/2017 a Q4\/2024<\/li>\n<li data-line=\"1\" dir=\"auto\">Total ADRs: 210.300<\/li>\n<li data-line=\"2\" dir=\"auto\">Pedi\u00e1tricos (&lt;18 anos): 20.065<\/li>\n<li data-line=\"3\" dir=\"auto\">Adultos (\u226518 anos): 112.508<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Sinais oculares:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Crian\u00e7as:<\/strong>&nbsp;14 System Organ Classes (SOCs) positivas<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Adultos:<\/strong>&nbsp;20 SOCs positivas<\/li>\n<li data-line=\"2\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Preferred Terms (PTs):<\/strong>\n<ul>\n<li data-line=\"3\" dir=\"auto\">Comuns a ambos: 126 PTs<\/li>\n<li data-line=\"4\" dir=\"auto\">\u00danicos em crian\u00e7as: 24 PTs<\/li>\n<li data-line=\"5\" dir=\"auto\"><strong>\u00danicos em adultos: 156 PTs (incluindo ocular rosacea)<\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Time-to-onset (TTO):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Crian\u00e7as:<\/strong>&nbsp;Mediana 0 dias<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Adultos:<\/strong>&nbsp;Mediana 14 dias<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Outros sinais oculares \u00fanicos em adultos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Sub-conjunctival fibrosis<\/li>\n<li data-line=\"1\" dir=\"auto\">Conjunctival papillae<\/li>\n<li data-line=\"2\" dir=\"auto\">Ocular rosacea<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Sinais comuns (ambos grupos):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Rebound eczema<\/li>\n<li data-line=\"1\" dir=\"auto\">Product use in unapproved indication<\/li>\n<li data-line=\"2\" dir=\"auto\">Therapeutic response shortened<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Impacto na Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Impacto na Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>ANTES:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Dupilumab \u2192 conjuntivite conhecida<\/li>\n<li data-line=\"1\" dir=\"auto\">N\u00e3o pens\u00e1vamos em rosacea ocular como evento adverso<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>AGORA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Dupilumab \u2192 perguntar sobre olhos secos, hiperemia, blefarite em TODA consulta<\/li>\n<li data-line=\"1\" dir=\"auto\">Se positivo \u2192 pode ser rosacea ocular induzida<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Benef\u00edcio:<\/strong>&nbsp;Diagn\u00f3stico precoce, tratamento espec\u00edfico, evitar descontinua\u00e7\u00e3o desnecess\u00e1ria do dupilumab<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Implementa\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Implementa\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Baseline (antes de iniciar dupilumab):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Examinar olhos<\/li>\n<li data-line=\"1\" dir=\"auto\">Documentar presen\u00e7a\/aus\u00eancia de blefarite, telangiectasias, MGD<\/li>\n<li data-line=\"2\" dir=\"auto\">Estabelecer baseline para compara\u00e7\u00e3o futura<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Seguimento (em TODA consulta):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Perguntar ativamente sobre:\n<ul>\n<li data-line=\"1\" dir=\"auto\">Olhos secos<\/li>\n<li data-line=\"2\" dir=\"auto\">Hiperemia<\/li>\n<li data-line=\"3\" dir=\"auto\">Sensa\u00e7\u00e3o de corpo estranho<\/li>\n<li data-line=\"4\" dir=\"auto\">Blefarite<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Se desenvolver sintomas:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Diferenciar:<\/strong>\n<ul>\n<li data-line=\"1\" dir=\"auto\"><strong>Conjuntivite al\u00e9rgica dupilumab (comum):<\/strong>&nbsp;Prurido, lacrimejamento, sem blefarite significativa<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Rosacea ocular (raro):<\/strong>&nbsp;Olhos secos, blefarite posterior, telangiectasias palpebrais, MGD<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Se diagnosticar rosacea ocular:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>N\u00c3O descontinuar dupilumab<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">Tratar rosacea ocular especificamente (ciclosporina t\u00f3pica, doxiciclina se necess\u00e1rio)<\/li>\n<li data-line=\"2\" dir=\"auto\">Encaminhar para oftalmologia se envolvimento corneal<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Cuidados e Limita\u00e7\u00f5es\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Cuidados e Limita\u00e7\u00f5es <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Limita\u00e7\u00f5es do estudo:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Vi\u00e9s de relato inerente ao sistema de farmacovigil\u00e2ncia<\/li>\n<li data-line=\"1\" dir=\"auto\">Causalidade n\u00e3o estabelecida definitivamente<\/li>\n<li data-line=\"2\" dir=\"auto\">Diferen\u00e7a crian\u00e7a\/adulto pode refletir vi\u00e9s diagn\u00f3stico<\/li>\n<li data-line=\"3\" dir=\"auto\">N\u00e3o h\u00e1 denominadores (n\u00e3o podemos calcular incid\u00eancia real)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Interpreta\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Maioria dos eventos oculares com dupilumab \u00e9 conjuntivite al\u00e9rgica conhecida<\/li>\n<li data-line=\"1\" dir=\"auto\">Rosacea ocular \u00e9 raro mas poss\u00edvel<\/li>\n<li data-line=\"2\" dir=\"auto\">Monitoramento ativo permite identifica\u00e7\u00e3o precoce<\/li>\n<li data-line=\"3\" dir=\"auto\">N\u00e3o \u00e9 contraindica\u00e7\u00e3o ao uso &#8211; \u00e9 sinal para monitorar<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"ATUALIZE\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>ATUALIZE <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"3 Refinamentos de Condutas Existentes\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>3 Refinamentos de Condutas Existentes <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"1. ISOTRETINO\u00cdNA VS DOXICICLINA: MECANISMOS IMUNOL\u00d3GICOS DIFERENTES\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>1. ISOTRETINO\u00cdNA VS DOXICICLINA: MECANISMOS IMUNOL\u00d3GICOS DIFERENTES <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Picosse F, et al. Int J Dermatol 2025 Mar;64(3):546-551<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;RCT Comparativo com Imunohistoqu\u00edmica<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;40 pacientes (20 isotretino\u00edna 0.3mg\/kg, 20 doxiciclina 100mg), 4 meses<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/ijd.17420\" target=\"_blank\">https:\/\/doi.org\/10.1111\/ijd.17420<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"O Que Mudou\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>O Que Mudou <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Antes:<\/strong><br \/>\n&#8220;Ambos s\u00e3o anti-inflamat\u00f3rios, escolha pelo perfil de eventos adversos&#8221;<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Agora:<\/strong><br \/>\nMecanismos DIFERENTES &#8211; isotretino\u00edna age primariamente nas gl\u00e2ndulas seb\u00e1ceas, doxiciclina no sistema neuroinflamat\u00f3rio<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Evid\u00eancia do Estudo\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Evid\u00eancia do Estudo <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Rosacea papulopustular moderada-grave<\/li>\n<li data-line=\"1\" dir=\"auto\">Incluindo rosacea ocular<\/li>\n<li data-line=\"2\" dir=\"auto\">Randomizado 1:1<\/li>\n<li data-line=\"3\" dir=\"auto\">4 meses de tratamento<\/li>\n<li data-line=\"4\" dir=\"auto\">Imunohistoqu\u00edmica pr\u00e9 e p\u00f3s-tratamento<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Biomarcadores Avaliados:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">NOS2 (Nitric Oxide Synthase)<\/li>\n<li data-line=\"1\" dir=\"auto\">VEGF (fator de crescimento endotelial vascular)<\/li>\n<li data-line=\"2\" dir=\"auto\">TRPV-1 (receptor vaniloide)<\/li>\n<li data-line=\"3\" dir=\"auto\">Cathelicidin LL37 (pept\u00eddeo antimicrobiano)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Resultados por Biomarcador\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resultados por Biomarcador <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Biomarcador<\/th>\n<th dir=\"ltr\">Localiza\u00e7\u00e3o<\/th>\n<th dir=\"ltr\">Isotretino\u00edna<\/th>\n<th dir=\"ltr\">Doxiciclina<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>NOS2<\/strong><\/td>\n<td dir=\"ltr\">Gl\u00e2ndulas seb\u00e1ceas<\/td>\n<td dir=\"ltr\">\u2193 p=0.030<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a significativa<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>NOS2<\/strong><\/td>\n<td dir=\"ltr\">Infiltrado inflamat\u00f3rio<\/td>\n<td dir=\"ltr\">\u2193 p&lt;0.001<\/td>\n<td dir=\"ltr\">\u2193 p=0.003<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>VEGF<\/strong><\/td>\n<td dir=\"ltr\">Intensidade<\/td>\n<td dir=\"ltr\">\u2193 p&lt;0.001<\/td>\n<td dir=\"ltr\">\u2193 p=0.020<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>VEGF<\/strong><\/td>\n<td dir=\"ltr\">Contagem de vasos<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<td dir=\"ltr\">\u2193 p=0.010<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>TRPV-1<\/strong><\/td>\n<td dir=\"ltr\">Gl\u00e2ndulas seb\u00e1ceas<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<td dir=\"ltr\">\u2193 p=0.041<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Cathelicidin LL37<\/strong><\/td>\n<td dir=\"ltr\">Gl\u00e2ndulas seb\u00e1ceas<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<td dir=\"ltr\">\u2193 p=0.007<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Cathelicidin LL37<\/strong><\/td>\n<td dir=\"ltr\">Infiltrado<\/td>\n<td dir=\"ltr\">\u2193 (ambos)<\/td>\n<td dir=\"ltr\">\u2193 (ambos)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Interpreta\u00e7\u00e3o Cl\u00ednica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Interpreta\u00e7\u00e3o Cl\u00ednica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>ISOTRETINO\u00cdNA age mais:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Nas gl\u00e2ndulas seb\u00e1ceas (\u2193 NOS2 glandular)<\/li>\n<li data-line=\"1\" dir=\"auto\">Reduzindo \u00f3xido n\u00edtrico na gl\u00e2ndula<\/li>\n<li data-line=\"2\" dir=\"auto\">Modulando fun\u00e7\u00e3o seb\u00e1cea<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>DOXICICLINA age mais:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">No sistema neuroinflamat\u00f3rio (\u2193 TRPV-1)<\/li>\n<li data-line=\"1\" dir=\"auto\">Em pept\u00eddeos antimicrobianos (\u2193 Cathelicidin glandular)<\/li>\n<li data-line=\"2\" dir=\"auto\">Na angiog\u00eanese (\u2193 contagem de vasos)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>AMBOS agem:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">No infiltrado inflamat\u00f3rio (\u2193 NOS2, \u2193 Cathelicidin)<\/li>\n<li data-line=\"1\" dir=\"auto\">Na intensidade vascular (\u2193 VEGF)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Aplica\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Aplica\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o-alvo:<\/strong>&nbsp;Rosacea papulopustular + ocular moderada-grave<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando escolher ISOTRETINO\u00cdNA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Meibomian gland dysfunction proeminente<\/li>\n<li data-line=\"1\" dir=\"auto\">Hipertrofia de gl\u00e2ndulas seb\u00e1ceas facial<\/li>\n<li data-line=\"2\" dir=\"auto\">Componente seb\u00e1ceo importante<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando escolher DOXICICLINA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Fotossensibilidade acentuada<\/li>\n<li data-line=\"1\" dir=\"auto\">Eritema\/flushing predominante<\/li>\n<li data-line=\"2\" dir=\"auto\">Componente neurovascular proeminente<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Como monitorar:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Isotretino\u00edna: Melhora de meibografia, redu\u00e7\u00e3o oleosidade<\/li>\n<li data-line=\"1\" dir=\"auto\">Doxiciclina: Redu\u00e7\u00e3o de eritema\/queima\u00e7\u00e3o, melhora fotossensibilidade<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Implica\u00e7\u00e3o\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Implica\u00e7\u00e3o <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Mecanismos complementares sugerem que&nbsp;<strong>combina\u00e7\u00e3o pode ser sin\u00e9rgica<\/strong>&nbsp;(n\u00e3o estudado ainda, mas racional te\u00f3rico existe).<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"2. PAR\u00c2METROS TOPOGR\u00c1FICOS CORNEAIS VARIAM POR SUBTIPO CUT\u00c2NEO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2. PAR\u00c2METROS TOPOGR\u00c1FICOS CORNEAIS VARIAM POR SUBTIPO CUT\u00c2NEO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Yesilirmak N, et al. J Fr Ophtalmol 2025 Mar;48(3):104403<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;Estudo Prospectivo Caso-Controle<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;180 olhos de 90 pacientes (30 phymatous, 30 erythematotelangiectatic, 30 papulopustular) + 60 olhos controles<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jfo.2024.104403\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jfo.2024.104403<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Achado Principal\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado Principal <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>Subtipo papulopustular tem c\u00f3rneas significativamente&nbsp;<strong>mais curvas<\/strong>&nbsp;(Kmean\/Kmax maiores) e&nbsp;<strong>mais finas<\/strong>(CCT menor) que erythematotelangiectatic e controles. TBUT \u00e9 menor e Meiboscore pior no papulopustular. Correla\u00e7\u00f5es significativas entre Kmax-CV, Kmax-TCT e Kmax-Meiboscore existem&nbsp;<strong>APENAS no subtipo papulopustular<\/strong>.<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Resultados Detalhados\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resultados Detalhados <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Topografia corneal:<\/strong><\/p>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Par\u00e2metro<\/th>\n<th dir=\"ltr\">Papulopustular<\/th>\n<th dir=\"ltr\">Erythematotelangiectatic<\/th>\n<th dir=\"ltr\">Phymatous<\/th>\n<th dir=\"ltr\">Controles<\/th>\n<th dir=\"ltr\">Signific\u00e2ncia<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Kmean<\/strong><\/td>\n<td dir=\"ltr\">Mais alto<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Mais alto<\/td>\n<td dir=\"ltr\">Mais baixo<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Kmax<\/strong><\/td>\n<td dir=\"ltr\">Mais alto<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Mais alto<\/td>\n<td dir=\"ltr\">Mais baixo<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>CCT<\/strong><\/td>\n<td dir=\"ltr\"><strong>Mais baixo<\/strong><\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Mais alto<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>TCT<\/strong><\/td>\n<td dir=\"ltr\"><strong>Mais baixo vs controles<\/strong><\/td>\n<td dir=\"ltr\">Normal<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>CV<\/strong><\/td>\n<td dir=\"ltr\">Sem diferen\u00e7a<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"ltr\">NS<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Par\u00e2metros de superf\u00edcie ocular:<\/strong><\/p>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Par\u00e2metro<\/th>\n<th dir=\"ltr\">Papulopustular<\/th>\n<th dir=\"ltr\">Erythematotelangiectatic<\/th>\n<th dir=\"ltr\">Phymatous<\/th>\n<th dir=\"ltr\">Controles<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>TBUT<\/strong><\/td>\n<td dir=\"ltr\"><strong>Mais baixo<\/strong><\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Meiboscore<\/strong><\/td>\n<td dir=\"ltr\"><strong>Pior<\/strong><\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Melhor<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Schirmer<\/strong><\/td>\n<td dir=\"ltr\">Sem diferen\u00e7a significativa entre grupos<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"auto\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Correla\u00e7\u00f5es significativas (APENAS no papulopustular):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Kmax-CV: p&lt;0.05<\/li>\n<li data-line=\"1\" dir=\"auto\">Kmax-TCT: p&lt;0.05<\/li>\n<li data-line=\"2\" dir=\"auto\">Kmax-Meiboscore: p&lt;0.05<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Correla\u00e7\u00f5es em todos os grupos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Idade-Kmean<\/li>\n<li data-line=\"1\" dir=\"auto\">Idade-Kmax<\/li>\n<li data-line=\"2\" dir=\"auto\">CV-TCT<\/li>\n<li data-line=\"3\" dir=\"auto\">CV-CCT<\/li>\n<li data-line=\"4\" dir=\"auto\">TCT-CCT<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Interpreta\u00e7\u00e3o Cl\u00ednica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Interpreta\u00e7\u00e3o Cl\u00ednica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Subtipo papulopustular:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Maior risco de adelga\u00e7amento corneal<\/li>\n<li data-line=\"1\" dir=\"auto\">Pior disfun\u00e7\u00e3o meibomiana<\/li>\n<li data-line=\"2\" dir=\"auto\">Filme lacrimal mais inst\u00e1vel<\/li>\n<li data-line=\"3\" dir=\"auto\">C\u00f3rneas mais encurvadas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Implica\u00e7\u00e3o:<\/strong>&nbsp;Papulopustular pode ter&nbsp;<strong>maior risco de complica\u00e7\u00f5es corneais<\/strong>&nbsp;e requer monitoramento mais rigoroso.<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Aplica\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Aplica\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando solicitar topografia corneal:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Baseline em todo paciente moderado-grave com rosacea ocular<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>ESPECIALMENTE em subtipo papulopustular<\/strong><\/li>\n<li data-line=\"2\" dir=\"auto\">Se sintomas visuais ou suspeita de astigmatismo irregular<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Como interpretar:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Kmean\/Kmax &gt;45D:<\/strong>&nbsp;Risco aumentado de progress\u00e3o<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>TCT &lt;520\u00b5m:<\/strong>&nbsp;Monitorar progress\u00e3o com topografias seriadas<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Correla\u00e7\u00e3o Meiboscore-Kmax:<\/strong>&nbsp;Quanto pior MGD, pior par\u00e2metros corneais<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>A\u00e7\u00e3o baseada no resultado:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Se alterado: Tratamento agressivo precoce<\/li>\n<li data-line=\"1\" dir=\"auto\">Evitar corticoide t\u00f3pico prolongado (pode adelga\u00e7ar mais)<\/li>\n<li data-line=\"2\" dir=\"auto\">Seguimento: Topografia anual<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Monitoramento especial em papulopustular:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Topografia baseline obrigat\u00f3ria<\/li>\n<li data-line=\"1\" dir=\"auto\">Avaliar Meiboscore regularmente<\/li>\n<li data-line=\"2\" dir=\"auto\">TBUT frequente<\/li>\n<li data-line=\"3\" dir=\"auto\">Threshold mais baixo para intensificar tratamento<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"3. QMR ELECTROTHERAPY: T\u00c9CNICA EMERGENTE PARA CASOS REFRAT\u00c1RIOS PEDI\u00c1TRICOS\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>3. QMR ELECTROTHERAPY: T\u00c9CNICA EMERGENTE PARA CASOS REFRAT\u00c1RIOS PEDI\u00c1TRICOS <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Surapaneni L, et al. Cornea 2025 Feb 1;44(2):157-162<br \/>\n<strong>Tipo de Estudo:<\/strong>&nbsp;Case Series Retrospectivo<br \/>\n<strong>Tamanho Amostral:<\/strong>&nbsp;3 pacientes pedi\u00e1tricos (idades 12, 15, 14 anos)<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1097\/ICO.0000000000003627\" target=\"_blank\">https:\/\/doi.org\/10.1097\/ICO.0000000000003627<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Contexto\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Contexto <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Quantum Molecular Resonance (QMR) Electrotherapy \u00e9 t\u00e9cnica&nbsp;<strong>off-label<\/strong>&nbsp;para rosacea ocular refrat\u00e1ria.<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Protocolo\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Protocolo <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>T\u00e9cnica:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">4 sess\u00f5es consecutivas<\/li>\n<li data-line=\"1\" dir=\"auto\">Intensidade: 5 (correspondendo em m\u00e9dia a 12W de pot\u00eancia, 60V voltagem, 200mA corrente)<\/li>\n<li data-line=\"2\" dir=\"auto\">Off-label use (consentimento informado obtido)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">3 pacientes femininas pedi\u00e1tricas<\/li>\n<li data-line=\"1\" dir=\"auto\">2 com neovasculariza\u00e7\u00e3o corneal estromal + eros\u00f5es epiteliais ponteadas<\/li>\n<li data-line=\"2\" dir=\"auto\">1 com cicatriz corneal + afinamento estromal paracentral<\/li>\n<li data-line=\"3\" dir=\"auto\">Todos refrat\u00e1rios a tratamento convencional<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Resultados\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resultados <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Acuidade visual:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">2\/3 pacientes: Melhora da acuidade visual<\/li>\n<li data-line=\"1\" dir=\"auto\">1\/3 paciente: Sem mudan\u00e7a (mas tinha cicatriz estabelecida)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Neovasculariza\u00e7\u00e3o corneal:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>3\/3 pacientes: Regress\u00e3o significativa<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">Documentado por fotografia seriada de l\u00e2mpada de fenda<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Remodelamento corneal:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">2\/3 pacientes: Evid\u00eancia de remodelamento em OCT de alta resolu\u00e7\u00e3o<\/li>\n<li data-line=\"1\" dir=\"auto\">Avaliado 2 meses p\u00f3s-QMR<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Imunossupressores t\u00f3picos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>3\/3 pacientes: Descontinuaram ap\u00f3s QMR<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">Permaneceram livres de sintomas por 1.5 anos de follow-up<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Eventos adversos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Nenhum reportado<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Aplica\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Aplica\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando pensar em QMR:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Crian\u00e7a com neovasculariza\u00e7\u00e3o corneal progressiva<\/li>\n<li data-line=\"1\" dir=\"auto\">Falha de pelo menos 2 linhas de tratamento<\/li>\n<li data-line=\"2\" dir=\"auto\">Risco de ambliopia ou perda visual permanente<\/li>\n<li data-line=\"3\" dir=\"auto\">Necessidade de imunossupressores prolongados<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Limita\u00e7\u00f5es importantes:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Equipamento&nbsp;<strong>N\u00c3O dispon\u00edvel comercialmente no Brasil<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">T\u00e9cnica off-label mesmo nos pa\u00edses onde existe<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Evid\u00eancia limitada<\/strong>&nbsp;(apenas 3 casos)<\/li>\n<li data-line=\"3\" dir=\"auto\">Mecanismo de a\u00e7\u00e3o n\u00e3o totalmente elucidado<\/li>\n<li data-line=\"4\" dir=\"auto\">Custo de equipamento proibitivo<\/li>\n<li data-line=\"5\" dir=\"auto\">Falta de aprova\u00e7\u00e3o ANVISA<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Status atual:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Considerar apenas em centros de refer\u00eancia terci\u00e1rios<\/li>\n<li data-line=\"1\" dir=\"auto\">Pode justificar encaminhamento internacional se recursos dispon\u00edveis<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>N\u00c3O \u00e9 op\u00e7\u00e3o de rotina<\/strong>&nbsp;&#8211; apenas casos excepcionalmente refrat\u00e1rios<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Take-home\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Take-home <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">QMR \u00e9&nbsp;<strong>prova de conceito<\/strong>&nbsp;promissora, mas ainda experimental. \u00datil conhecer para casos extremos, mas n\u00e3o para implementa\u00e7\u00e3o rotineira.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"BOM SABER\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>BOM SABER <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"4 Conhecimentos \u00dateis para a Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>4 Conhecimentos \u00dateis para a Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"1. FOTOPROTE\u00c7\u00c3O \u00c9 AINDA MAIS CR\u00cdTICA: PACIENTES T\u00caM MENOR MED PARA UVA E UVB\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>1. FOTOPROTE\u00c7\u00c3O \u00c9 AINDA MAIS CR\u00cdTICA: PACIENTES T\u00caM MENOR MED PARA UVA E UVB <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Wei R, et al. Photodermatol Photoimmunol Photomed 2025 May;41(3):e70019<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/phpp.70019\" target=\"_blank\">https:\/\/doi.org\/10.1111\/phpp.70019<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Achado\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Achado <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Pacientes com rosacea t\u00eam Minimal Erythema Dose (MED)&nbsp;<strong>objetivamente menor<\/strong>&nbsp;para UVA (p&lt;0.05) e UVB (p\u22640.001) comparado a controles saud\u00e1veis. Sem diferen\u00e7a significativa entre subtipos ETR vs PPR.<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"M\u00e9todo\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>M\u00e9todo <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">70 pacientes com rosacea<\/li>\n<li data-line=\"1\" dir=\"auto\">100 controles saud\u00e1veis<\/li>\n<li data-line=\"2\" dir=\"auto\">Subtipos: Erythematotelangiectatic e Papulopustular<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Medi\u00e7\u00f5es:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">MED-UVA e MED-UVB usando SUV-2000 solar UV simulator<\/li>\n<li data-line=\"1\" dir=\"auto\">An\u00e1lise comparativa entre grupos<\/li>\n<li data-line=\"2\" dir=\"auto\">Correla\u00e7\u00e3o com idade, fototipo, ANA, CEA scale<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Resultados\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resultados <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Par\u00e2metro<\/th>\n<th dir=\"ltr\">Rosacea<\/th>\n<th dir=\"ltr\">Controles<\/th>\n<th dir=\"ltr\">Signific\u00e2ncia<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>MED-UVA<\/strong><\/td>\n<td dir=\"ltr\">Menor<\/td>\n<td dir=\"ltr\">Refer\u00eancia<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>MED-UVB<\/strong><\/td>\n<td dir=\"ltr\">Menor<\/td>\n<td dir=\"ltr\">Refer\u00eancia<\/td>\n<td dir=\"ltr\">p\u22640.001<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>ETR vs PPR<\/strong><\/td>\n<td dir=\"ltr\">Sem diferen\u00e7a<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"ltr\">p&gt;0.05<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Relev\u00e2ncia Cl\u00ednica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Relev\u00e2ncia Cl\u00ednica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Explica:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Por que UV \u00e9 trigger t\u00e3o potente em rosacea<\/li>\n<li data-line=\"1\" dir=\"auto\">Base fisiol\u00f3gica para fotoprote\u00e7\u00e3o rigorosa<\/li>\n<li data-line=\"2\" dir=\"auto\">N\u00e3o \u00e9 apenas flushing subjetivo &#8211; \u00e9 resposta eritematosa objetivamente aumentada<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Implica\u00e7\u00e3o pr\u00e1tica:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Fotoprote\u00e7\u00e3o N\u00c3O \u00e9 &#8220;recomenda\u00e7\u00e3o gen\u00e9rica&#8221;<\/li>\n<li data-line=\"1\" dir=\"auto\">\u00c9 necessidade fisiol\u00f3gica comprovada<\/li>\n<li data-line=\"2\" dir=\"auto\">Limiar de eritema biologicamente mais baixo<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Recomenda\u00e7\u00e3o para Pacientes\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Recomenda\u00e7\u00e3o para Pacientes <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>&#8220;Seu limiar de vermelhid\u00e3o ao sol \u00e9 biologicamente mais baixo que pessoas sem rosacea. Isso foi medido objetivamente. Protetor FPS 50+ com PPD alto \u00e9 necess\u00e1rio, reaplicar a cada 2 horas, evitar exposi\u00e7\u00e3o entre 10h-16h. N\u00e3o \u00e9 exagero, \u00e9 fisiologia.&#8221;<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"2. INSIGHTS FISIOPATOL\u00d3GICOS: TOLL-LIKE RECEPTORS E COMPLEMENTO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2. INSIGHTS FISIOPATOL\u00d3GICOS: TOLL-LIKE RECEPTORS E COMPLEMENTO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Mohamed-Noriega K, et al. Cornea 2025 Apr 1;44(4):525-537<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1097\/ICO.0000000000003785\" target=\"_blank\">https:\/\/doi.org\/10.1097\/ICO.0000000000003785<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Mecanismo Atualizado (Review Abrangente)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Mecanismo Atualizado (Review Abrangente) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Ativa\u00e7\u00e3o de TLR (Toll-Like Receptors):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>TLR2:<\/strong>&nbsp;Reconhece produtos bacterianos da parede celular<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Principais ant\u00edgenos:<\/strong>&nbsp;Staphylococcus, produtos de Demodex<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Resultado:<\/strong>&nbsp;Ativa\u00e7\u00e3o cascata inflamat\u00f3ria inata<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Sistema Complemento:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Envolvido na inflama\u00e7\u00e3o cr\u00f4nica da superf\u00edcie ocular<\/li>\n<li data-line=\"1\" dir=\"auto\">Amplifica resposta imune<\/li>\n<li data-line=\"2\" dir=\"auto\">Perpetua inflama\u00e7\u00e3o<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Exotoxinas Citol\u00edticas:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Efeito t\u00f3xico DIRETO na superf\u00edcie ocular<\/li>\n<li data-line=\"1\" dir=\"auto\">N\u00e3o \u00e9 apenas resposta imune<\/li>\n<li data-line=\"2\" dir=\"auto\">Les\u00e3o tecidual direta<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Implica\u00e7\u00e3o Terap\u00eautica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Implica\u00e7\u00e3o Terap\u00eautica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por que tetraciclinas funcionam:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">N\u00e3o \u00e9 s\u00f3 anti-Demodex<\/li>\n<li data-line=\"1\" dir=\"auto\">Efeito anti-inflamat\u00f3rio via modula\u00e7\u00e3o de TLR<\/li>\n<li data-line=\"2\" dir=\"auto\">Reduz resposta downstream<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por que higiene palpebral ajuda:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Remove ant\u00edgenos bacterianos que ativam TLR<\/li>\n<li data-line=\"1\" dir=\"auto\">Reduz carga antig\u00eanica<\/li>\n<li data-line=\"2\" dir=\"auto\">Diminui trigger inflamat\u00f3rio<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por que ciclosporina funciona:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Bloqueia downstream da ativa\u00e7\u00e3o TLR\/complemento<\/li>\n<li data-line=\"1\" dir=\"auto\">Modula c\u00e9lulas T<\/li>\n<li data-line=\"2\" dir=\"auto\">Reduz inflama\u00e7\u00e3o cr\u00f4nica<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Futuro (Mencionado no Review)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Futuro (Mencionado no Review) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Em pesquisa:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Inibidores espec\u00edficos de TLR2<\/li>\n<li data-line=\"1\" dir=\"auto\">Moduladores do complemento (j\u00e1 usados em outras doen\u00e7as oculares)<\/li>\n<li data-line=\"2\" dir=\"auto\">Terapias direcionadas ao microbioma<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Timeline:<\/strong>&nbsp;&gt;5 anos para aplica\u00e7\u00e3o cl\u00ednica<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Take-home\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Take-home <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Entender fisiopatologia explica&nbsp;<strong>POR QUE<\/strong>&nbsp;tratamentos funcionam e ajuda a combinar terapias racionalmente.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"3. PEDIATRIA: DIAGN\u00d3STICO TARDIO \u00c9 COMUM E PREJUDICIAL\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>3. PEDIATRIA: DIAGN\u00d3STICO TARDIO \u00c9 COMUM E PREJUDICIAL <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;\u00d6zkan G, et al. (dados secund\u00e1rios do paper de ciclosporina)<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1080\/09273948.2025.2553219\" target=\"_blank\">https:\/\/doi.org\/10.1080\/09273948.2025.2553219<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Realidade do Diagn\u00f3stico Pedi\u00e1trico\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Realidade do Diagn\u00f3stico Pedi\u00e1trico <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>No estudo de \u00d6zkan:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">45% (10\/22 pacientes) tiveram diagn\u00f3stico tardio<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>M\u00e9dia de delay:<\/strong>&nbsp;10.0\u00b12.7 meses<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Consequ\u00eancia:<\/strong>&nbsp;91% (20\/22) j\u00e1 tinham envolvimento corneal ao diagn\u00f3stico<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Cal\u00e1zio recorrente:<\/strong>&nbsp;Presente em 7\/22 pacientes<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Sinais de Alerta que Pais Raramente Relatam Espontaneamente\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Sinais de Alerta que Pais Raramente Relatam Espontaneamente <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Piscar excessivo<\/li>\n<li data-line=\"1\" dir=\"auto\">Fotofobia (crian\u00e7a evita luz, esconde rosto)<\/li>\n<li data-line=\"2\" dir=\"auto\">Esfregar olhos frequentemente<\/li>\n<li data-line=\"3\" dir=\"auto\">&#8220;Cisco&#8221; constante<\/li>\n<li data-line=\"4\" dir=\"auto\">Cal\u00e1zio recorrente (&gt;2 epis\u00f3dios)<\/li>\n<li data-line=\"5\" dir=\"auto\">Hiperemia ocular matinal<\/li>\n<li data-line=\"6\" dir=\"auto\">Crostas palpebrais<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Novo Protocolo de Screening Pedi\u00e1trico\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Novo Protocolo de Screening Pedi\u00e1trico <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>1. Todo paciente pedi\u00e1trico com rosacea cut\u00e2nea:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Examinar olhos no baseline<\/li>\n<li data-line=\"1\" dir=\"auto\">N\u00e3o esperar queixas espont\u00e2neas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>2. Cal\u00e1zio recorrente (&gt;2 epis\u00f3dios):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Investigar rosacea ocular MESMO SEM rosacea cut\u00e2nea evidente<\/li>\n<li data-line=\"1\" dir=\"auto\">Pode preceder manifesta\u00e7\u00f5es cut\u00e2neas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>3. Blefarite cr\u00f4nica + dermatite facial:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Pensar em rosacea ocular<\/li>\n<li data-line=\"1\" dir=\"auto\">Avaliar para envolvimento sist\u00eamico<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>4. Threshold baixo para encaminhamento:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Oftalmologia pedi\u00e1trica para biomicroscopia<\/li>\n<li data-line=\"1\" dir=\"auto\">N\u00e3o esperar progress\u00e3o<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Meta\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Meta <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Reduzir delay diagn\u00f3stico de 10 meses para &lt;1 m\u00eas<\/strong><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Consequ\u00eancia do Delay\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Consequ\u00eancia do Delay <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Envolvimento corneal estabelecido<\/li>\n<li data-line=\"1\" dir=\"auto\">Neovasculariza\u00e7\u00e3o<\/li>\n<li data-line=\"2\" dir=\"auto\">Cicatrizes<\/li>\n<li data-line=\"3\" dir=\"auto\">Astigmatismo irregular<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>Ambliopia em casos graves<\/strong><\/li>\n<li data-line=\"5\" dir=\"auto\">Perda visual potencialmente irrevers\u00edvel<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"4. PREVAL\u00caNCIA REAL: OS N\u00daMEROS QUE VOC\u00ca PRECISA SABER PARA ARGUMENTAR\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>4. PREVAL\u00caNCIA REAL: OS N\u00daMEROS QUE VOC\u00ca PRECISA SABER PARA ARGUMENTAR <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Kirkpatrick RH, et al. (dados detalhados da meta-an\u00e1lise)<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Meta-an\u00e1lise em Detalhes\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Meta-an\u00e1lise em Detalhes <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>DIAGNOSED OCULAR ROSACEA:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Preval\u00eancia:<\/strong>&nbsp;10.3%<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>N total:<\/strong>&nbsp;124.093 pacientes<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Estudos:<\/strong>&nbsp;11<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Varia\u00e7\u00e3o:<\/strong>&nbsp;0.03% a 65% (heterogeneidade ALTA)<\/li>\n<li data-line=\"4\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Tend\u00eancia temporal:<\/strong>&nbsp;Estudos mais recentes reportam preval\u00eancias MENORES\n<ul>\n<li data-line=\"5\" dir=\"auto\">Poss\u00edvel vi\u00e9s: gap diagn\u00f3stico aumentando ou mudan\u00e7a de crit\u00e9rios<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>OCULAR INVOLVEMENT (quando examinados sistematicamente):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Preval\u00eancia:<\/strong>&nbsp;44.3%<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>N total:<\/strong>&nbsp;1.747 pacientes<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Estudos:<\/strong>&nbsp;17<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Conclus\u00e3o:<\/strong>&nbsp;77% dos casos N\u00c3O s\u00e3o diagnosticados na pr\u00e1tica cl\u00ednica usual<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Como Usar Esses N\u00fameros\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Como Usar Esses N\u00fameros <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>1. Justificar exame oftalmol\u00f3gico:<\/strong><\/p>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>&#8220;Meta-an\u00e1lise de 2025 com 125.840 pacientes demonstra que 44.3% dos pacientes com rosacea cut\u00e2nea t\u00eam envolvimento ocular, mas apenas 10.3% recebem diagn\u00f3stico. Exame oftalmol\u00f3gico \u00e9 necess\u00e1rio para n\u00e3o deixar passar 3 em cada 4 casos.&#8221;<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>2. Argumentar com plano de sa\u00fade:<\/strong><\/p>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>&#8220;Solicita\u00e7\u00e3o baseada em evid\u00eancia n\u00edvel 1A (meta-an\u00e1lise, Canadian Journal of Ophthalmology 2025). Preval\u00eancia de envolvimento ocular: 44.3%. N\u00e3o \u00e9 custo desnecess\u00e1rio &#8211; probabilidade pr\u00e9-teste \u00e9 alta.&#8221;<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>3. Educar paciente:<\/strong><\/p>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>&#8220;Quase metade das pessoas com rosacea na pele t\u00eam os olhos afetados, mesmo sem sintomas. \u00c9 importante examinar.&#8221;<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Frase Pronta para Relat\u00f3rio M\u00e9dico\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Frase Pronta para Relat\u00f3rio M\u00e9dico <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-blockquote\">\n<blockquote dir=\"auto\">\n<p>&#8220;Solicita\u00e7\u00e3o de avalia\u00e7\u00e3o oftalmol\u00f3gica fundamentada em meta-an\u00e1lise recente (Kirkpatrick et al. 2025, Canadian Journal of Ophthalmology, PMID 40373823) demonstrando preval\u00eancia de envolvimento ocular em 44.3% dos pacientes com rosacea cut\u00e2nea, com gap diagn\u00f3stico de 77% quando screening sistem\u00e1tico n\u00e3o \u00e9 realizado. N\u00famero necess\u00e1rio para screening: 3 pacientes para identificar 1 caso n\u00e3o diagnosticado.&#8221;<\/p>\n<\/blockquote>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"FIQUE DE OLHO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>FIQUE DE OLHO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Tend\u00eancias Emergentes e Controv\u00e9rsias\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Tend\u00eancias Emergentes e Controv\u00e9rsias <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"1. PIPELINE TERAP\u00caUTICO: O QUE VEM POR A\u00cd\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>1. PIPELINE TERAP\u00caUTICO: O QUE VEM POR A\u00cd <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Mohamed-Noriega K, et al. (se\u00e7\u00e3o &#8220;Future Directions&#8221;)<br \/>\n<strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1097\/ICO.0000000000003785\" target=\"_blank\">https:\/\/doi.org\/10.1097\/ICO.0000000000003785<\/a><\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Abordagens em Pesquisa\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Abordagens em Pesquisa <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Abordagem<\/th>\n<th dir=\"ltr\">Mecanismo<\/th>\n<th dir=\"ltr\">Status<\/th>\n<th dir=\"ltr\">Timeline<\/th>\n<th dir=\"ltr\">Racional<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Inibidores TLR2<\/strong><\/td>\n<td dir=\"ltr\">Bloqueia ativa\u00e7\u00e3o TLR2 por ant\u00edgenos bacterianos<\/td>\n<td dir=\"ltr\">Pesquisa b\u00e1sica<\/td>\n<td dir=\"ltr\">&gt;5 anos<\/td>\n<td dir=\"ltr\">Atua na causa raiz inflamat\u00f3ria<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Moduladores Complemento<\/strong><\/td>\n<td dir=\"ltr\">Inibe cascata do complemento<\/td>\n<td dir=\"ltr\">Pr\u00e9-cl\u00ednico<\/td>\n<td dir=\"ltr\">3-5 anos<\/td>\n<td dir=\"ltr\">J\u00e1 aprovados para outras indica\u00e7\u00f5es oculares<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Anti-IL-31<\/strong><\/td>\n<td dir=\"ltr\">Bloqueia prurido neurog\u00eanico<\/td>\n<td dir=\"ltr\">Fase 2 (dermatite)<\/td>\n<td dir=\"ltr\">2-3 anos off-label<\/td>\n<td dir=\"ltr\">Pode ajudar sensa\u00e7\u00e3o de corpo estranho<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Luz pulsada intensa (IPL)<\/strong><\/td>\n<td dir=\"ltr\">Trata MGD de base<\/td>\n<td dir=\"ltr\">J\u00e1 dispon\u00edvel off-label<\/td>\n<td dir=\"ltr\">Dispon\u00edvel<\/td>\n<td dir=\"ltr\">Custo \u00e9 barreira principal<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Conceitos Emergentes\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Conceitos Emergentes <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Microbioma como biomarcador progn\u00f3stico:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Status:<\/strong>&nbsp;Pesquisa cl\u00ednica inicial<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Potencial:<\/strong>&nbsp;Perfil de Demodex + microbioma palpebral pode predizer resposta<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Timeline:<\/strong>&nbsp;3-5 anos at\u00e9 valida\u00e7\u00e3o cl\u00ednica<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Implica\u00e7\u00e3o:<\/strong>&nbsp;Medicina personalizada &#8211; saber QUAL paciente responde a QUAL droga<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Biomarcadores lacrimais:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>O que \u00e9:<\/strong>&nbsp;MMP-9, IL-6, IL-17 no filme lacrimal como marcadores de atividade<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Potencial:<\/strong>&nbsp;Monitoramento objetivo (n\u00e3o apenas cl\u00ednico) da resposta<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Timeline:<\/strong>&nbsp;2-3 anos para teste comercial<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Vantagem:<\/strong>&nbsp;Point-of-care, quantitativo, rastre\u00e1vel<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"2. CONTROV\u00c9RSIA: CORTICOSTEROIDES T\u00d3PICOS - QUANDO E POR QUANTO TEMPO?\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2. CONTROV\u00c9RSIA: CORTICOSTEROIDES T\u00d3PICOS &#8211; QUANDO E POR QUANTO TEMPO? <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fonte:<\/strong>&nbsp;Consenso impl\u00edcito em m\u00faltiplos papers (\u00d6zkan, Mohamed-Noriega, Ortiz-Morales)<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Posi\u00e7\u00f5es Divergentes\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Posi\u00e7\u00f5es Divergentes <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Posi\u00e7\u00e3o Conservadora:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Apenas fase aguda<\/li>\n<li data-line=\"1\" dir=\"auto\">M\u00e1ximo 2 semanas<\/li>\n<li data-line=\"2\" dir=\"auto\">Riscos: Glaucoma, catarata, adelga\u00e7amento corneal<\/li>\n<li data-line=\"3\" dir=\"auto\">Base: Princ\u00edpios gerais de uso de corticoide ocular<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Posi\u00e7\u00e3o Pragm\u00e1tica:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Pulse therapy (1 semana on, 2 semanas off) pode ser mantida<\/li>\n<li data-line=\"1\" dir=\"auto\">Benef\u00edcio em inflama\u00e7\u00e3o grave supera risco se monitorado<\/li>\n<li data-line=\"2\" dir=\"auto\">Fluorometolona tem menos risco que dexametasona<\/li>\n<li data-line=\"3\" dir=\"auto\">Base: Experi\u00eancia cl\u00ednica em casos refrat\u00e1rios<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Evid\u00eancias Pendentes\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Evid\u00eancias Pendentes <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>O que falta:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">RCT comparando protocolos pulse vs curto prazo<\/li>\n<li data-line=\"1\" dir=\"auto\">Dados de seguran\u00e7a de longo prazo (&gt;3 meses)<\/li>\n<li data-line=\"2\" dir=\"auto\">Identifica\u00e7\u00e3o de subgrupos com maior risco<\/li>\n<li data-line=\"3\" dir=\"auto\">Biomarcadores de resposta ao corticoide<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Consenso Atual 2025\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Consenso Atual 2025 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Baseado nos papers analisados:<\/strong><\/p>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\"><strong>Fase aguda (todos concordam):<\/strong>&nbsp;7-14 dias OK<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Se melhora incompleta:<\/strong>&nbsp;Switch para ciclosporina (n\u00e3o manter corticoide)<\/li>\n<li data-line=\"2\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Se recidiva grave:<\/strong>&nbsp;Pulse 3 dias\/semana PODE ser considerado com:\n<ul>\n<li data-line=\"3\" dir=\"auto\">Press\u00e3o intraocular (PIO) semanal<\/li>\n<li data-line=\"4\" dir=\"auto\">Biomicroscopia regular<\/li>\n<li data-line=\"5\" dir=\"auto\">Tempo limitado (m\u00e1ximo 3 meses)<\/li>\n<\/ul>\n<\/li>\n<li data-line=\"6\" dir=\"auto\"><strong>NUNCA monoterapia de longo prazo<\/strong><\/li>\n<\/ol>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Recomenda\u00e7\u00e3o Pr\u00e1tica\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Recomenda\u00e7\u00e3o Pr\u00e1tica <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Usar corticoide como &#8220;ponte&#8221; para ciclosporina, n\u00e3o como manuten\u00e7\u00e3o.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"3. PEDIATRIA: LIMIAR PARA TRATAMENTO SIST\u00caMICO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>3. PEDIATRIA: LIMIAR PARA TRATAMENTO SIST\u00caMICO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Controv\u00e9rsia Atual\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Controv\u00e9rsia Atual <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando escalar de t\u00f3picos para isotretino\u00edna\/doxiciclina em crian\u00e7as?<\/strong><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Faltam:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Crit\u00e9rios padronizados de gravidade pedi\u00e1trica espec\u00edficos<\/li>\n<li data-line=\"1\" dir=\"auto\">Dados de seguran\u00e7a isotretino\u00edna &lt;12 anos (off-label)<\/li>\n<li data-line=\"2\" dir=\"auto\">Compara\u00e7\u00e3o head-to-head azitromicina vs doxiciclina em pediatria<\/li>\n<li data-line=\"3\" dir=\"auto\">Guidelines pedi\u00e1tricas espec\u00edficas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fontes dos papers:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">\u00d6zkan: Usou azitromicina sist\u00eamica em fase aguda<\/li>\n<li data-line=\"1\" dir=\"auto\">Surapaneni: 3 casos eram adolescentes (12-15 anos)<\/li>\n<li data-line=\"2\" dir=\"auto\">Ortiz-Morales (review): Sugere threshold baixo<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Tend\u00eancia Observada nos Papers\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Tend\u00eancia Observada nos Papers <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Consenso emergente:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Threshold MAIS BAIXO<\/strong>&nbsp;para tratar agressivamente<\/li>\n<li data-line=\"1\" dir=\"auto\">Justificativa: Delay de 10 meses = sequelas visuais<\/li>\n<li data-line=\"2\" dir=\"auto\">Prefer\u00eancia: Azitromicina &gt;6 anos, evitar doxiciclina &lt;8 anos<\/li>\n<li data-line=\"3\" dir=\"auto\">Isotretino\u00edna: Considerar &gt;12 anos se refrat\u00e1rio<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Algoritmo Sugerido (baseado nos papers)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Algoritmo Sugerido (baseado nos papers) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Leve:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Higiene palpebral<\/li>\n<li data-line=\"1\" dir=\"auto\">L\u00e1grimas artificiais<\/li>\n<li data-line=\"2\" dir=\"auto\">Antibi\u00f3tico t\u00f3pico<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Moderado:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Adicionar azitromicina sist\u00eamica<\/li>\n<li data-line=\"1\" dir=\"auto\">Se &gt;8 anos: doxiciclina \u00e9 op\u00e7\u00e3o<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Grave ou envolvimento corneal:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Tratamento sist\u00eamico obrigat\u00f3rio<\/li>\n<li data-line=\"1\" dir=\"auto\">Se &gt;12 anos e refrat\u00e1rio: considerar isotretino\u00edna off-label<\/li>\n<li data-line=\"2\" dir=\"auto\">Ciclosporina t\u00f3pica SEMPRE como manuten\u00e7\u00e3o<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Meta:<\/strong>&nbsp;N\u00e3o esperar progress\u00e3o &#8211; tratar precocemente.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"AN\u00c1LISE COMPARATIVA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>AN\u00c1LISE COMPARATIVA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Dados dos Estudos por Tratamento\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Dados dos Estudos por Tratamento <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"ISOTRETINO\u00cdNA - Meta-an\u00e1lise King et al.\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>ISOTRETINO\u00cdNA &#8211; Meta-an\u00e1lise King et al. <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/jdv.20315\" target=\"_blank\">https:\/\/doi.org\/10.1111\/jdv.20315<\/a><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong>&nbsp;1.445 pacientes em 16 estudos<br \/>\n<strong>Dose estudada:<\/strong>&nbsp;\u22640.5mg\/kg\/dia<br \/>\n<strong>Dura\u00e7\u00e3o t\u00edpica:<\/strong>&nbsp;12-16 semanas<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Efic\u00e1cia\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Efic\u00e1cia <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Desfecho<\/th>\n<th dir=\"ltr\">Resultado<\/th>\n<th dir=\"ltr\">Signific\u00e2ncia<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Redu\u00e7\u00e3o de les\u00f5es<\/strong><\/td>\n<td dir=\"ltr\">Large effect (SMD&gt;0.8)<\/td>\n<td dir=\"ltr\">p=0.03<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Redu\u00e7\u00e3o de eritema<\/strong><\/td>\n<td dir=\"ltr\">Large effect (SMD&gt;0.8)<\/td>\n<td dir=\"ltr\">p=0.01<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Superioridade vs t\u00f3picos<\/strong><\/td>\n<td dir=\"ltr\">Moderate effect (SMD&gt;0.5)<\/td>\n<td dir=\"ltr\">p=0.03<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Manuten\u00e7\u00e3o 16 sem p\u00f3s-tratamento<\/strong><\/td>\n<td dir=\"ltr\">Les\u00f5es -70%, Eritema -47%<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Recorr\u00eancia<\/strong><\/td>\n<td dir=\"ltr\">35% aos 5.5 meses<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Seguran\u00e7a\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Seguran\u00e7a <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Par\u00e2metro<\/th>\n<th dir=\"ltr\">Taxa<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Eventos adversos s\u00e9rios<\/strong><\/td>\n<td dir=\"auto\">0.4% (3\/1.445)<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Piora da rosacea<\/strong><\/td>\n<td dir=\"ltr\">0.4% (3 pacientes)<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Descontinua\u00e7\u00e3o<\/strong><\/td>\n<td dir=\"auto\">~8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"CICLOSPORINA T\u00d3PICA 0.05% - Estudo \u00d6zkan et al.\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>CICLOSPORINA T\u00d3PICA 0.05% &#8211; Estudo \u00d6zkan et al. <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1080\/09273948.2025.2553219\" target=\"_blank\">https:\/\/doi.org\/10.1080\/09273948.2025.2553219<\/a><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong>&nbsp;22 pacientes pedi\u00e1tricos (&lt;16 anos)<br \/>\n<strong>Protocolo:<\/strong>&nbsp;Manuten\u00e7\u00e3o ap\u00f3s fase aguda com sist\u00eamico<br \/>\n<strong>Dura\u00e7\u00e3o:<\/strong>&nbsp;23.8\u00b19.9 meses follow-up<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Efic\u00e1cia\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Efic\u00e1cia <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Desfecho<\/th>\n<th dir=\"ltr\">Baseline<\/th>\n<th dir=\"ltr\">Final<\/th>\n<th dir=\"ltr\">Signific\u00e2ncia<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>BCVA (olhos pior vis\u00e3o)<\/strong><\/td>\n<td dir=\"ltr\">0.34\u00b10.27 logMAR<\/td>\n<td dir=\"ltr\">0.02\u00b10.04 logMAR<\/td>\n<td dir=\"ltr\">p&lt;0.001<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Cilindro<\/strong><\/td>\n<td dir=\"ltr\">-2.21\u00b11.33 D<\/td>\n<td dir=\"ltr\">Redu\u00e7\u00e3o significativa<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>NIBUT<\/strong><\/td>\n<td dir=\"ltr\">Baixo<\/td>\n<td dir=\"ltr\">Melhora significativa<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Meibografia<\/strong><\/td>\n<td dir=\"ltr\">Perda glandular<\/td>\n<td dir=\"ltr\">Redu\u00e7\u00e3o da perda<\/td>\n<td dir=\"ltr\">p&lt;0.05<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Recorr\u00eancia<\/strong><\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<td dir=\"auto\">9% (2\/22)<\/td>\n<td dir=\"auto\">&#8211;<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Seguran\u00e7a\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Seguran\u00e7a <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Par\u00e2metro<\/th>\n<th dir=\"ltr\">Resultado<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Descontinua\u00e7\u00e3o por EA<\/strong><\/td>\n<td dir=\"auto\">0%<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Ard\u00eancia inicial<\/strong><\/td>\n<td dir=\"ltr\">~30% (transit\u00f3ria)<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Eventos graves<\/strong><\/td>\n<td dir=\"auto\">0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"DOXICICLINA vs ISOTRETINO\u00cdNA - Estudo Picosse et al.\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>DOXICICLINA vs ISOTRETINO\u00cdNA &#8211; Estudo Picosse et al. <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/ijd.17420\" target=\"_blank\">https:\/\/doi.org\/10.1111\/ijd.17420<\/a><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong>&nbsp;40 pacientes (20 ISO, 20 DOXY)<br \/>\n<strong>Dura\u00e7\u00e3o:<\/strong>&nbsp;4 meses<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Biomarcadores (Imunohistoqu\u00edmica)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Biomarcadores (Imunohistoqu\u00edmica) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Biomarcador<\/th>\n<th dir=\"ltr\">Localiza\u00e7\u00e3o<\/th>\n<th dir=\"ltr\">Isotretino\u00edna 0.3mg\/kg<\/th>\n<th dir=\"ltr\">Doxiciclina 100mg<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>NOS2<\/strong><\/td>\n<td dir=\"ltr\">Gl\u00e2ndulas seb\u00e1ceas<\/td>\n<td dir=\"ltr\">\u2193 p=0.030<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>NOS2<\/strong><\/td>\n<td dir=\"ltr\">Infiltrado inflamat\u00f3rio<\/td>\n<td dir=\"ltr\">\u2193 p&lt;0.001<\/td>\n<td dir=\"ltr\">\u2193 p=0.003<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>VEGF<\/strong><\/td>\n<td dir=\"ltr\">Intensidade<\/td>\n<td dir=\"ltr\">\u2193 p&lt;0.001<\/td>\n<td dir=\"ltr\">\u2193 p=0.020<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>VEGF<\/strong><\/td>\n<td dir=\"ltr\">Contagem vasos<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<td dir=\"ltr\">\u2193 p=0.010<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>TRPV-1<\/strong><\/td>\n<td dir=\"ltr\">Gl\u00e2ndulas<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<td dir=\"ltr\">\u2193 p=0.041<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Cathelicidin LL37<\/strong><\/td>\n<td dir=\"ltr\">Gl\u00e2ndulas<\/td>\n<td dir=\"ltr\">Sem mudan\u00e7a<\/td>\n<td dir=\"ltr\">\u2193 p=0.007<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Interpreta\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Isotretino\u00edna age mais nas gl\u00e2ndulas (\u2193 NOS2 glandular)<\/li>\n<li data-line=\"1\" dir=\"auto\">Doxiciclina age mais no sistema neurovascular (\u2193 TRPV-1, \u2193 LL37 glandular)<\/li>\n<li data-line=\"2\" dir=\"auto\">Ambos reduzem inflama\u00e7\u00e3o sist\u00eamica (\u2193 NOS2 infiltrado)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"DUPILUMAB - Farmacovigil\u00e2ncia Zhou et al.\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>DUPILUMAB &#8211; Farmacovigil\u00e2ncia Zhou et al. <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103<\/a><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong>&nbsp;210.300 ADRs (FAERS database)<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Sinais de Rosacea Ocular\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Sinais de Rosacea Ocular <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Popula\u00e7\u00e3o<\/th>\n<th dir=\"ltr\">Sinal de Rosacea Ocular<\/th>\n<th dir=\"ltr\">TTO Mediana<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Adultos<\/strong><\/td>\n<td dir=\"ltr\">Presente<\/td>\n<td dir=\"ltr\">14 dias<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Crian\u00e7as<\/strong><\/td>\n<td dir=\"ltr\">Ausente<\/td>\n<td dir=\"ltr\">0 dias<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Outros sinais oculares \u00fanicos em adultos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Sub-conjunctival fibrosis<\/li>\n<li data-line=\"1\" dir=\"auto\">Conjunctival papillae<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Nota:<\/strong>&nbsp;Estudo de farmacovigil\u00e2ncia &#8211; causalidade n\u00e3o estabelecida definitivamente, mas sinal identificado.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"TOPOGRAFIA CORNEAL - Estudo Yesilirmak et al.\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>TOPOGRAFIA CORNEAL &#8211; Estudo Yesilirmak et al. <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jfo.2024.104403\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jfo.2024.104403<\/a><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Popula\u00e7\u00e3o:<\/strong>&nbsp;90 pacientes rosacea (30 cada subtipo), 30 controles<\/p>\n<\/div>\n<div class=\"el-h4\">\n<h4 data-heading=\"Par\u00e2metros por Subtipo Cut\u00e2neo\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Par\u00e2metros por Subtipo Cut\u00e2neo <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h4>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Par\u00e2metro<\/th>\n<th dir=\"ltr\">Papulopustular<\/th>\n<th dir=\"ltr\">Erythematotelangiectatic<\/th>\n<th dir=\"ltr\">Phymatous<\/th>\n<th dir=\"ltr\">Controles<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Kmean<\/strong><\/td>\n<td dir=\"auto\">\u2191\u2191<\/td>\n<td dir=\"auto\">\u2191<\/td>\n<td dir=\"auto\">\u2191\u2191<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Kmax<\/strong><\/td>\n<td dir=\"auto\">\u2191\u2191<\/td>\n<td dir=\"auto\">\u2191<\/td>\n<td dir=\"auto\">\u2191\u2191<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>CCT<\/strong><\/td>\n<td dir=\"auto\">\u2193<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>TBUT<\/strong><\/td>\n<td dir=\"auto\">\u2193\u2193<\/td>\n<td dir=\"auto\">\u2193<\/td>\n<td dir=\"auto\">\u2193<\/td>\n<td dir=\"ltr\">Normal<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Meiboscore<\/strong><\/td>\n<td dir=\"ltr\">Pior<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Intermedi\u00e1rio<\/td>\n<td dir=\"ltr\">Melhor<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Correla\u00e7\u00f5es \u00fanicas no papulopustular:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Kmax-CV (p&lt;0.05)<\/li>\n<li data-line=\"1\" dir=\"auto\">Kmax-TCT (p&lt;0.05)<\/li>\n<li data-line=\"2\" dir=\"auto\">Kmax-Meiboscore (p&lt;0.05)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Conclus\u00e3o:<\/strong>&nbsp;Papulopustular tem maior risco de altera\u00e7\u00f5es corneais.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"ALGORITMO DE DECIS\u00c3O TERAP\u00caUTICA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>ALGORITMO DE DECIS\u00c3O TERAP\u00caUTICA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Fluxograma Baseado nos Estudos 2025\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Fluxograma Baseado nos Estudos 2025 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">SUSPEITA ROSACEA OCULAR\n(Rosacea cut\u00e2nea + sintomas oculares OU cal\u00e1zio recorrente)\n         |\n         v\nCONFIRMA\u00c7\u00c3O DIAGN\u00d3STICA\nBiomicroscopia: blefarite posterior, MGD, hiperemia, telangiectasias\n         |\n         v\nAVALIA\u00c7\u00c3O DE GRAVIDADE\n         |\n    _____|_____\n   |           |\n   v           v\nLEVE        MODERADO-GRAVE\n(Sem c\u00f3rnea) (C\u00f3rnea envolvida ou sintomas graves)\n   |               |\n   v               v\nPRIMEIRA LINHA   PRIMEIRA LINHA\n\u2022 Higiene palp.  ESCOLHA:\n\u2022 L\u00e1grima artif.\n\u2022 Doxiciclina    A) ISOTRETINO\u00cdNA\n  OU               0.3-0.5mg\/kg\/dia\n\u2022 Azitromicina     12-16 semanas\n                   \n12 semanas       B) DOXICICLINA\n   |               100mg\/dia\n   v               + Corticoide pulse\nRESPONDEU?         12-16 semanas\n   |               \nSim|    N\u00e3o       12 semanas\n   v     v           |\nMANUTEN\u00c7\u00c3O         v\n   |            RESPONDEU?\n   v               |\nCiclosporina    Sim|    N\u00e3o\n0.05% 2x\/dia       v     v\n6 meses         MANUTEN\u00c7\u00c3O REFRAT\u00c1RIO\n   |               |         |\n   v               v         v\nRevis\u00e3o        Ciclosporina \u2022 Switch ISO\u2194DOXY\nanual          0.05%        \u2022 Add-on t\u00f3picos\n               + Revis\u00e3o    \u2022 QMR (se dispon\u00edvel)\n               semestral    \u2022 Cirurgia debulking\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"PEDIATRIA (&lt;12 anos)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>PEDIATRIA (&lt;12 anos) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">Preferir:\n\u2022 Azitromicina (se &gt;6 anos)\n\u2022 Ciclosporina t\u00f3pica SEMPRE como manuten\u00e7\u00e3o\n\nEvitar:\n\u2022 Doxiciclina &lt;8 anos (dentes)\n\u2022 Isotretino\u00edna &lt;12 anos (n\u00e3o estudado - off-label)\n\nSe refrat\u00e1rio:\n\u2022 Considerar ISO off-label com consentimento\n\u2022 QMR em centros especializados (se dispon\u00edvel)\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Crit\u00e9rios de Escolha - Primeira Linha\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Crit\u00e9rios de Escolha &#8211; Primeira Linha <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Para ISOTRETINO\u00cdNA:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Para ISOTRETINO\u00cdNA: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Indica\u00e7\u00f5es preferenciais:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Meibomian gland dysfunction proeminente<\/li>\n<li data-line=\"1\" dir=\"auto\">Hipertrofia seb\u00e1cea facial<\/li>\n<li data-line=\"2\" dir=\"auto\">Envolvimento corneal (neovasculariza\u00e7\u00e3o, infiltrados)<\/li>\n<li data-line=\"3\" dir=\"auto\">Falha pr\u00e9via com tetraciclinas<\/li>\n<li data-line=\"4\" dir=\"auto\">Componente seb\u00e1ceo importante<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Contraindica\u00e7\u00f5es:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Gravidez\/amamenta\u00e7\u00e3o (ABSOLUTA)<\/li>\n<li data-line=\"1\" dir=\"auto\">Hepatopatia grave<\/li>\n<li data-line=\"2\" dir=\"auto\">Dislipidemia n\u00e3o controlada<\/li>\n<li data-line=\"3\" dir=\"auto\">Impossibilidade de contracep\u00e7\u00e3o (mulheres)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Para DOXICICLINA:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Para DOXICICLINA: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Indica\u00e7\u00f5es preferenciais:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Eritema\/flushing predominante<\/li>\n<li data-line=\"1\" dir=\"auto\">Fotossensibilidade acentuada<\/li>\n<li data-line=\"2\" dir=\"auto\">Componente neurovascular importante<\/li>\n<li data-line=\"3\" dir=\"auto\">Paciente n\u00e3o pode usar isotretino\u00edna (gesta\u00e7\u00e3o, custo)<\/li>\n<li data-line=\"4\" dir=\"auto\">Necessidade de resposta r\u00e1pida (com pulse corticoide)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Contraindica\u00e7\u00f5es:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">&lt;8 anos (dentes)<\/li>\n<li data-line=\"1\" dir=\"auto\">Gesta\u00e7\u00e3o<\/li>\n<li data-line=\"2\" dir=\"auto\">Hipersensibilidade a tetraciclinas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Crit\u00e9rios de RESPOSTA (12-16 semanas)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Crit\u00e9rios de RESPOSTA (12-16 semanas) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Resposta Adequada:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resposta Adequada: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Redu\u00e7\u00e3o \u226550% de les\u00f5es inflamat\u00f3rias palpebrais<\/li>\n<li data-line=\"1\" dir=\"auto\">Melhora subjetiva \u226550% (escala anal\u00f3gica)<\/li>\n<li data-line=\"2\" dir=\"auto\">NIBUT melhora \u22655 segundos OU Schirmer \u2191\u22653mm<\/li>\n<li data-line=\"3\" dir=\"auto\">SEM progress\u00e3o corneal<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>A\u00e7\u00e3o:<\/strong>&nbsp;Completar tratamento, iniciar manuten\u00e7\u00e3o<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Resposta Parcial:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resposta Parcial: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Redu\u00e7\u00e3o 25-50% les\u00f5es<\/li>\n<li data-line=\"1\" dir=\"auto\">Melhora subjetiva 25-50%<\/li>\n<li data-line=\"2\" dir=\"auto\">Estabiliza\u00e7\u00e3o mas sem melhora significativa<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>A\u00e7\u00e3o:<\/strong>&nbsp;Otimizar (\u2191 dose se poss\u00edvel, add-on t\u00f3picos), aguardar +4 semanas<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"N\u00e3o Resposta:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00e3o Resposta: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Redu\u00e7\u00e3o &lt;25% les\u00f5es<\/li>\n<li data-line=\"1\" dir=\"auto\">Progress\u00e3o corneal (\u2191 neovasculariza\u00e7\u00e3o, novos infiltrados, \u2193 acuidade visual)<\/li>\n<li data-line=\"2\" dir=\"auto\">Eventos adversos intoler\u00e1veis<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>A\u00e7\u00e3o:<\/strong>&nbsp;SWITCH obrigat\u00f3rio<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"CHECKLISTS PARA O CONSULT\u00d3RIO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>CHECKLISTS PARA O CONSULT\u00d3RIO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Checklist Pr\u00e9-Tratamento com ISOTRETINO\u00cdNA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Checklist Pr\u00e9-Tratamento com ISOTRETINO\u00cdNA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Exames Obrigat\u00f3rios\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Exames Obrigat\u00f3rios <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Hemograma completo<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Lipidograma completo (CT, HDL, LDL, TG)<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">TGO\/TGP<\/li>\n<li data-line=\"3\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"3\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">\u03b2-hCG s\u00e9rico (mulheres em idade f\u00e9rtil)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Rastreamentos\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Rastreamentos <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Biomicroscopia ocular (documentar baseline c\u00f3rnea)<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Fotos padronizadas (face + p\u00e1lpebras + olhos abertos)<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Acuidade visual (ambos os olhos)<\/li>\n<li data-line=\"3\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"3\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Press\u00e3o intraocular (se usar corticoide)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Documenta\u00e7\u00e3o\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Documenta\u00e7\u00e3o <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Relat\u00f3rio m\u00e9dico com CID L71.8 + H16.2<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Fotos padronizadas pr\u00e9-tratamento<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Documentar falha pr\u00e9via: &#8220;Doxiciclina 100mg\/dia por 12 semanas &#8211; falha terap\u00eautica&#8221;<\/li>\n<li data-line=\"3\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"3\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Relat\u00f3rio oftalmol\u00f3gico confirmando envolvimento ocular<\/li>\n<li data-line=\"4\" dir=\"auto\">[ ]&nbsp;<strong>Termo de consentimento isotretino\u00edna assinado<\/strong><\/li>\n<li data-line=\"5\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>[ ]&nbsp;<strong>Contraceptivo confirmado<\/strong>&nbsp;(mulheres):\n<ul>\n<li data-line=\"6\" dir=\"auto\">M\u00e9todo 1: <strong><strong>__<\/strong><\/strong><\/li>\n<li data-line=\"7\" dir=\"auto\">M\u00e9todo 2: <strong><strong>__<\/strong><\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Contraindica\u00e7\u00f5es Absolutas\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Contraindica\u00e7\u00f5es Absolutas <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Gravidez ou amamenta\u00e7\u00e3o<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Hipersensibilidade conhecida \u00e0 isotretino\u00edna<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Hipervitaminose A<\/li>\n<li data-line=\"3\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"3\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Hepatopatia grave (Child B ou C)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Contraindica\u00e7\u00f5es Relativas\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Contraindica\u00e7\u00f5es Relativas <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Dislipidemia n\u00e3o controlada \u2192 Otimizar, reavaliar em 4 semanas<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Depress\u00e3o ativa \u2192 Avaliar risco-benef\u00edcio, considerar psiquiatria<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Diabetes descompensado \u2192 Risco de \u2191 TG, controlar antes<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Checklist de Monitoramento - ISOTRETINO\u00cdNA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Checklist de Monitoramento &#8211; ISOTRETINO\u00cdNA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 4\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 4 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Sintomas subjetivos: melhora? Eventos adversos?<\/li>\n<li data-line=\"1\" dir=\"auto\">[ ]&nbsp;<strong>Lipidograma<\/strong>: Se TG &gt;300mg\/dL, reduzir dose ou suspender<\/li>\n<li data-line=\"2\" dir=\"auto\">[ ]&nbsp;<strong>TGO\/TGP<\/strong>: Se &gt;3x LSN, suspender<\/li>\n<li data-line=\"3\" dir=\"auto\">[ ]&nbsp;<strong>\u03b2-hCG<\/strong>: Repetir em mulheres f\u00e9rteis<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 8\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 8 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Avalia\u00e7\u00e3o cl\u00ednica: contagem les\u00f5es, eritema<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Biomicroscopia: progress\u00e3o corneal?<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">NIBUT \/ Schirmer: melhorou?<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 12\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 12 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" dir=\"auto\">[ ]&nbsp;<strong>Lipidograma e TGO\/TGP<\/strong>: Controle<\/li>\n<li data-line=\"1\" dir=\"auto\">[ ]&nbsp;<strong>Decis\u00e3o:<\/strong>&nbsp;Manter at\u00e9 16 semanas OU switch se n\u00e3o resposta<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Fotos comparativas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 16 (Final)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 16 (Final) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Avalia\u00e7\u00e3o final: resposta completa?<\/li>\n<li data-line=\"1\" dir=\"auto\">[ ]&nbsp;<strong>\u03b2-hCG final<\/strong>&nbsp;(mulheres)<\/li>\n<li data-line=\"2\" dir=\"auto\">[ ]&nbsp;<strong>Plano manuten\u00e7\u00e3o:<\/strong>&nbsp;Ciclosporina OU Azitromicina 2x\/sem<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Checklist de Monitoramento - CICLOSPORINA T\u00d3PICA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Checklist de Monitoramento &#8211; CICLOSPORINA T\u00d3PICA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 2\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 2 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Tolerabilidade: ard\u00eancia aceit\u00e1vel?<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Ader\u00eancia: usando 2x\/dia?<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 4\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 4 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">NIBUT: baseline <strong><em>s \u2192 atual <\/em><\/strong>s (meta: \u2191\u22655s)<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Sintomas: ard\u00eancia, lacrimejamento, hiperemia<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Semana 12\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Semana 12 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" dir=\"auto\">[ ]&nbsp;<strong>Resposta completa?<\/strong>&nbsp;Sim \u2192 Manter 6 meses total<\/li>\n<li data-line=\"1\" dir=\"auto\">[ ]&nbsp;<strong>Resposta parcial?<\/strong>&nbsp;Add-on: otimizar higiene, considerar azitromicina sist\u00eamica<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Meibografia: perda glandular estabilizou?<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"M\u00eas 6 (Final manuten\u00e7\u00e3o)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>M\u00eas 6 (Final manuten\u00e7\u00e3o) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Decis\u00e3o: Continuar? Reduzir para 1x\/dia? Suspender?<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Se suspender: reavaliar em 1 m\u00eas (detectar recidiva precoce)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Checklist de SCREENING em Paciente com Rosacea Cut\u00e2nea\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Checklist de SCREENING em Paciente com Rosacea Cut\u00e2nea <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Perguntas Obrigat\u00f3rias (mesmo sem queixa espont\u00e2nea):\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Perguntas Obrigat\u00f3rias (mesmo sem queixa espont\u00e2nea): <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">&#8220;Seus olhos ficam secos ou irritados?&#8221;<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">&#8220;Sente areia ou corpo estranho nos olhos?&#8221;<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">&#8220;Tem fotofobia (incomoda luz)?&#8221;<\/li>\n<li data-line=\"3\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"3\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">&#8220;Os olhos lacrimejam muito?&#8221;<\/li>\n<li data-line=\"4\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"4\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">&#8220;P\u00e1lpebras vermelhas ou inchadas pela manh\u00e3?&#8221;<\/li>\n<li data-line=\"5\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"5\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">&#8220;J\u00e1 teve cal\u00e1zio (ter\u00e7ol interno)?&#8221;<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Se \u22652 respostas SIM:<\/strong>&nbsp;Exame obrigat\u00f3rio<\/p>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Exame Simplificado no Consult\u00f3rio:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Exame Simplificado no Consult\u00f3rio: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Inspe\u00e7\u00e3o p\u00e1lpebras: hiperemia margem, telangiectasias<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Express\u00e3o meibomianas: secre\u00e7\u00e3o espessa\/turva?<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Hiperemia conjuntival<\/li>\n<li data-line=\"3\" dir=\"auto\">[ ]&nbsp;<strong>Se algum achado:<\/strong>&nbsp;Encaminhar oftalmologia<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Pediatria - LIMIAR MAIS BAIXO:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Pediatria &#8211; LIMIAR MAIS BAIXO: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Cal\u00e1zio &gt;1 epis\u00f3dio \u2192 Examinar SEMPRE<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Piscar excessivo ou esfregar olhos \u2192 Investigar<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Rosacea cut\u00e2nea moderada-grave \u2192 Oftalmologia de rotina<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Sinais de Alerta (Suspender e Investigar)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Sinais de Alerta (Suspender e Investigar) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"ISOTRETINO\u00cdNA:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>ISOTRETINO\u00cdNA: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">TG &gt;400 mg\/dL (risco pancreatite)<\/li>\n<li data-line=\"1\" dir=\"auto\">TGO\/TGP &gt;5x LSN<\/li>\n<li data-line=\"2\" dir=\"auto\">Idea\u00e7\u00e3o suicida ou depress\u00e3o grave<\/li>\n<li data-line=\"3\" dir=\"auto\">Sintomas visuais novos (vis\u00e3o borrada, dor ocular intensa)<\/li>\n<li data-line=\"4\" dir=\"auto\">Sintomas gastrointestinais graves (suspeita de pancreatite)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"CICLOSPORINA T\u00d3PICA:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>CICLOSPORINA T\u00d3PICA: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Dor ocular intensa progressiva<\/li>\n<li data-line=\"1\" dir=\"auto\">Piora aguda da vis\u00e3o<\/li>\n<li data-line=\"2\" dir=\"auto\">Suspeita de infec\u00e7\u00e3o (secre\u00e7\u00e3o purulenta)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"M\u00c9TRICAS DE SUCESSO TERAP\u00caUTICO\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>M\u00c9TRICAS DE SUCESSO TERAP\u00caUTICO <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Timeline de Avalia\u00e7\u00e3o - Tratamento Sist\u00eamico\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Timeline de Avalia\u00e7\u00e3o &#8211; Tratamento Sist\u00eamico <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Semana<\/th>\n<th dir=\"ltr\">Avaliar<\/th>\n<th dir=\"ltr\">Resposta M\u00ednima<\/th>\n<th dir=\"ltr\">Resposta Ideal<\/th>\n<th dir=\"ltr\">A\u00e7\u00e3o se Insuficiente<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"auto\"><strong>2<\/strong><\/td>\n<td dir=\"ltr\">Tolerabilidade EA<\/td>\n<td dir=\"ltr\">Sem EA graves<\/td>\n<td dir=\"ltr\">Sem EA<\/td>\n<td dir=\"ltr\">Ajustar sintom\u00e1ticos<\/td>\n<\/tr>\n<tr>\n<td dir=\"auto\"><strong>4<\/strong><\/td>\n<td dir=\"ltr\">Melhora subjetiva<\/td>\n<td dir=\"ltr\">\u219325% sintomas<\/td>\n<td dir=\"ltr\">\u219350% sintomas<\/td>\n<td dir=\"ltr\">Otimizar dose<\/td>\n<\/tr>\n<tr>\n<td dir=\"auto\"><strong>8<\/strong><\/td>\n<td dir=\"ltr\">Les\u00f5es palpebrais<\/td>\n<td dir=\"auto\">\u219330%<\/td>\n<td dir=\"auto\">\u219350%<\/td>\n<td dir=\"ltr\">Considerar add-on t\u00f3pico<\/td>\n<\/tr>\n<tr>\n<td dir=\"auto\"><strong>12<\/strong><\/td>\n<td dir=\"ltr\">NIBUT, Schirmer<\/td>\n<td dir=\"ltr\">Estabiliza\u00e7\u00e3o<\/td>\n<td dir=\"ltr\">\u21915s NIBUT<\/td>\n<td dir=\"ltr\"><strong>Decis\u00e3o switch<\/strong>&nbsp;se sem melhora<\/td>\n<\/tr>\n<tr>\n<td dir=\"auto\"><strong>16<\/strong><\/td>\n<td dir=\"ltr\">Acuidade visual<\/td>\n<td dir=\"ltr\">Sem piora<\/td>\n<td dir=\"ltr\">Melhora<\/td>\n<td dir=\"ltr\"><strong>Switch obrigat\u00f3rio<\/strong>&nbsp;se deteriora\u00e7\u00e3o<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Defini\u00e7\u00f5es de Resposta\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Defini\u00e7\u00f5es de Resposta <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Resposta Completa\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resposta Completa <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Redu\u00e7\u00e3o \u226575% les\u00f5es inflamat\u00f3rias palpebrais&nbsp;<strong>E<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">Melhora subjetiva \u226575% (escala anal\u00f3gica 0-10)&nbsp;<strong>E<\/strong><\/li>\n<li data-line=\"2\" dir=\"auto\">NIBUT \u226510 segundos OU Schirmer \u226510mm&nbsp;<strong>E<\/strong><\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Sem envolvimento corneal ativo<\/strong>&nbsp;(sem novos infiltrados\/neovasculariza\u00e7\u00e3o)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Resposta Parcial\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resposta Parcial <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Redu\u00e7\u00e3o 50-74% les\u00f5es inflamat\u00f3rias&nbsp;<strong>OU<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">Melhora subjetiva 50-74%&nbsp;<strong>E<\/strong><\/li>\n<li data-line=\"2\" dir=\"auto\">Estabiliza\u00e7\u00e3o par\u00e2metros (NIBUT, Schirmer)&nbsp;<strong>MAS<\/strong>&nbsp;n\u00e3o melhora significativa&nbsp;<strong>E<\/strong><\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Sem progress\u00e3o corneal<\/strong><\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"N\u00e3o Resposta\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>N\u00e3o Resposta <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Redu\u00e7\u00e3o &lt;50% les\u00f5es<\/li>\n<li data-line=\"1\" dir=\"auto\">Melhora subjetiva &lt;50%<\/li>\n<li data-line=\"2\" dir=\"auto\">Progress\u00e3o corneal documentada<\/li>\n<li data-line=\"3\" dir=\"auto\">Piora acuidade visual (\u22651 linha Snellen)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Scores Validados\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Scores Validados <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"OSDI (Ocular Surface Disease Index)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>OSDI (Ocular Surface Disease Index) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>C\u00e1lculo:<\/strong><\/p>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">[(Soma pontos) \u00f7 (N quest\u00f5es respondidas)] \u00d7 25\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Interpreta\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Normal:<\/strong>&nbsp;0-12 pontos<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Leve:<\/strong>&nbsp;13-22 pontos<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Moderado:<\/strong>&nbsp;23-32 pontos<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Grave:<\/strong>&nbsp;33-100 pontos<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Melhora cl\u00ednica significativa:<\/strong>&nbsp;\u0394 \u2265 10 pontos<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Aplica\u00e7\u00e3o pr\u00e1tica:<\/strong>&nbsp;Aplicar baseline e a cada 4-8 semanas<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"SPEED (Standard Patient Evaluation of Eye Dryness)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>SPEED (Standard Patient Evaluation of Eye Dryness) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>C\u00e1lculo:<\/strong><\/p>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">Frequ\u00eancia (0-3) \u00d7 Severidade (0-4) para 8 sintomas\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Interpreta\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Normal:<\/strong>&nbsp;0-4<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Olho seco:<\/strong>&nbsp;\u22655<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Melhora cl\u00ednica significativa:<\/strong>&nbsp;\u0394 \u2265 3 pontos<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Vantagem:<\/strong>&nbsp;R\u00e1pido (2 minutos), f\u00e1cil reaplica\u00e7\u00e3o<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"CEA (Clinical Erythema Assessment)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>CEA (Clinical Erythema Assessment) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Escala 0-4:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>0<\/strong>&nbsp;= Sem eritema<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>1<\/strong>&nbsp;= Leve (pink, difuso)<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>2<\/strong>&nbsp;= Moderado (vermelho, difuso)<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>3<\/strong>&nbsp;= Grave (vermelho escuro, difuso)<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>4<\/strong>&nbsp;= Muito grave (vermelho escuro-viol\u00e1ceo)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Meta tratamento:<\/strong>&nbsp;\u22641<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Nota:<\/strong>&nbsp;Eritema facial correlaciona com gravidade ocular<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Par\u00e2metros Objetivos\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Par\u00e2metros Objetivos <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"NIBUT (Non-Invasive Break-Up Time)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>NIBUT (Non-Invasive Break-Up Time) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Normal:<\/strong>&nbsp;&gt;10 segundos<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Alterado:<\/strong>&nbsp;&lt;10 segundos<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Grave:<\/strong>&nbsp;&lt;5 segundos<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Meta tratamento:<\/strong>&nbsp;Atingir \u226510s OU \u2191\u22655s do baseline<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Teste de Schirmer (sem anestesia)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Teste de Schirmer (sem anestesia) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Normal:<\/strong>&nbsp;\u226510mm em 5 minutos<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Olho seco:<\/strong>&nbsp;&lt;10mm<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Grave:<\/strong>&nbsp;&lt;5mm<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Meta tratamento:<\/strong>&nbsp;Atingir \u226510mm OU \u2191\u22655mm<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Meibografia (avalia\u00e7\u00e3o perda glandular)\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Meibografia (avalia\u00e7\u00e3o perda glandular) <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Meiboscore (Escala 0-3):<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>0:<\/strong>&nbsp;Sem perda (&lt;25%)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>1:<\/strong>&nbsp;Perda leve (25-50%)<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>2:<\/strong>&nbsp;Perda moderada (50-75%)<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>3:<\/strong>&nbsp;Perda grave (&gt;75%)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Meta:<\/strong>&nbsp;Estabilizar (impedir progress\u00e3o)<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Protocolo de Seguimento Fotogr\u00e1fico\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Protocolo de Seguimento Fotogr\u00e1fico <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Fotos obrigat\u00f3rias:<\/strong><\/p>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\">Face frontal (avaliar eritema, p\u00e1pulas)<\/li>\n<li data-line=\"1\" dir=\"auto\">P\u00e1lpebras fechadas (avaliar blefarite, telangiectasias)<\/li>\n<li data-line=\"2\" dir=\"auto\">Olho aberto (avaliar hiperemia conjuntival)<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Se c\u00f3rnea envolvida:<\/strong>&nbsp;Fluoresce\u00edna (documentar infiltrados, neovasculariza\u00e7\u00e3o)<\/li>\n<\/ol>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Timing:<\/strong>&nbsp;Baseline, 8 semanas, 16 semanas, 6 meses<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Padroniza\u00e7\u00e3o:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Mesma dist\u00e2ncia, ilumina\u00e7\u00e3o, \u00e2ngulo<\/li>\n<li data-line=\"1\" dir=\"auto\">Sem maquiagem<\/li>\n<li data-line=\"2\" dir=\"auto\">Antes de qualquer col\u00edrio<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Quando Declarar FALHA e MUDAR\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Quando Declarar FALHA e MUDAR <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Crit\u00e9rios Objetivos para SWITCH:\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Crit\u00e9rios Objetivos para SWITCH: <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Switch obrigat\u00f3rio se:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">16 semanas de tratamento sist\u00eamico sem atingir resposta parcial<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Progress\u00e3o corneal documentada (novos infiltrados, \u2191 neovasculariza\u00e7\u00e3o)<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Piora acuidade visual (\u22652 linhas Snellen)<\/li>\n<li data-line=\"3\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"3\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Eventos adversos intoler\u00e1veis<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Considerar switch\/add-on se:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul class=\"contains-task-list\">\n<li data-line=\"0\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"0\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">12 semanas com resposta parcial mas estagna\u00e7\u00e3o<\/li>\n<li data-line=\"1\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"1\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Recidiva &lt;3 meses ap\u00f3s suspens\u00e3o<\/li>\n<li data-line=\"2\" data-task=\"\" class=\"task-list-item\" dir=\"auto\"><input data-line=\"2\" type=\"checkbox\" class=\"task-list-item-checkbox\" aria-label=\"Task\">Resposta inicial boa mas perda de efic\u00e1cia<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"TAKE HOME MESSAGES\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>TAKE HOME MESSAGES <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"As 5 A\u00e7\u00f5es Priorit\u00e1rias do Ano\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>As 5 A\u00e7\u00f5es Priorit\u00e1rias do Ano <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"1. EXAMINE OS OLHOS DE TODO PACIENTE COM ROSACEA - SEMPRE\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>1. EXAMINE OS OLHOS DE TODO PACIENTE COM ROSACEA &#8211; SEMPRE <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>O qu\u00ea:<\/strong>&nbsp;Screening ativo com perguntas espec\u00edficas + inspe\u00e7\u00e3o simples das p\u00e1lpebras e conjuntiva<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando:<\/strong>&nbsp;TODA consulta de paciente com rosacea cut\u00e2nea, independente de queixa espont\u00e2nea<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Para quem:<\/strong>&nbsp;100% dos seus pacientes com rosacea<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Como:<\/strong><\/p>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\">Perguntas obrigat\u00f3rias: olhos secos, areia, fotofobia, lacrimejamento<\/li>\n<li data-line=\"1\" dir=\"auto\">Inspe\u00e7\u00e3o: hiperemia margem palpebral, telangiectasias, express\u00e3o meibomiana<\/li>\n<li data-line=\"2\" dir=\"auto\">Se \u22652 sintomas OU \u22651 sinal: encaminhar oftalmologia<\/li>\n<\/ol>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por qu\u00ea:<\/strong>&nbsp;44% t\u00eam doen\u00e7a, mas s\u00f3 10% s\u00e3o diagnosticados (gap de 400%). Voc\u00ea pode evitar sequelas visuais permanentes.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base:<\/strong>&nbsp;Kirkpatrick meta-an\u00e1lise, 125.840 pacientes, n\u00edvel 1A<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"2. USE CICLOSPORINA T\u00d3PICA 0.05% COMO MANUTEN\u00c7\u00c3O\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>2. USE CICLOSPORINA T\u00d3PICA 0.05% COMO MANUTEN\u00c7\u00c3O <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>O qu\u00ea:<\/strong>&nbsp;Ap\u00f3s controlar fase aguda com sist\u00eamico, manter ciclosporina t\u00f3pica 2x\/dia por 6 meses<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando:<\/strong>&nbsp;Assim que suspender\/reduzir sist\u00eamico (semana 12-16)<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Para quem:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Pediatria: OBRIGAT\u00d3RIO<\/strong><\/li>\n<li data-line=\"1\" dir=\"auto\">Adultos: Moderado-grave ou recidiva pr\u00e9via<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por qu\u00ea:<\/strong>&nbsp;Reduz recorr\u00eancia de 60% para 9%, melhora NIBUT, preserva fun\u00e7\u00e3o visual<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Como prescrever:<\/strong><\/p>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">Ciclosporina 0,05% emuls\u00e3o oft\u00e1lmica\n1 gota em cada olho afetado, 2 vezes ao dia, por 6 meses\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base:<\/strong>&nbsp;\u00d6zkan 22 pacientes pedi\u00e1tricos, 23.8 meses follow-up, n\u00edvel 2B<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"3. ISOTRETINO\u00cdNA BAIXA DOSE \u00c9 PRIMEIRA LINHA EM CASOS GRAVES\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>3. ISOTRETINO\u00cdNA BAIXA DOSE \u00c9 PRIMEIRA LINHA EM CASOS GRAVES <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>O qu\u00ea:<\/strong>&nbsp;Prescrever isotretino\u00edna 0.3-0.5mg\/kg\/dia por 12-16 semanas para rosacea ocular moderada-grave<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando:<\/strong>&nbsp;Envolvimento corneal OU falha com doxiciclina OU meibomian gland dysfunction grave<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Para quem:<\/strong>&nbsp;Adultos e adolescentes &gt;12 anos (off-label &lt;12 anos)<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Impacto esperado:<\/strong>&nbsp;70% de redu\u00e7\u00e3o les\u00f5es, efeito mantido 4 meses p\u00f3s-tratamento<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>N\u00e3o esquecer:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">2 m\u00e9todos contraceptivos (mulheres f\u00e9rteis)<\/li>\n<li data-line=\"1\" dir=\"auto\">\u03b2-hCG negativo antes, durante, ap\u00f3s<\/li>\n<li data-line=\"2\" dir=\"auto\">Lipidograma + TGO\/TGP semana 0, 4, 12<\/li>\n<li data-line=\"3\" dir=\"auto\">Termo de consentimento<\/li>\n<li data-line=\"4\" dir=\"auto\">Receitu\u00e1rio especial (2 vias)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base:<\/strong>&nbsp;King meta-an\u00e1lise, 1.445 pacientes, 16 estudos, n\u00edvel 1A<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"4. EM PEDIATRIA: LIMIAR BAIXO PARA TRATAR - DELAY CAUSA AMBLIOPIA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>4. EM PEDIATRIA: LIMIAR BAIXO PARA TRATAR &#8211; DELAY CAUSA AMBLIOPIA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>O qu\u00ea:<\/strong>&nbsp;Investigar e tratar agressivamente rosacea ocular em crian\u00e7as, sem esperar &#8220;para ver se melhora&#8221;<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Cal\u00e1zio &gt;2 epis\u00f3dios \u2192 Investigar rosacea ocular<\/li>\n<li data-line=\"1\" dir=\"auto\">Rosacea cut\u00e2nea confirmada \u2192 Screening oftalmol\u00f3gico obrigat\u00f3rio<\/li>\n<li data-line=\"2\" dir=\"auto\">Blefarite cr\u00f4nica + dermatite facial \u2192 Pensar rosacea ocular<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Para quem:<\/strong>&nbsp;Toda crian\u00e7a com rosacea cut\u00e2nea OU cal\u00e1zio recorrente OU blefarite cr\u00f4nica inexplicada<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Por qu\u00ea:<\/strong>&nbsp;M\u00e9dia de delay diagn\u00f3stico \u00e9 10 meses, 91% j\u00e1 t\u00eam envolvimento corneal quando diagnosticados. C\u00f3rnea opacificada em crian\u00e7a = ambliopia irrevers\u00edvel.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Protocolo pedi\u00e1trico:<\/strong><\/p>\n<\/div>\n<div class=\"el-ol\">\n<ol>\n<li data-line=\"0\" dir=\"auto\">Azitromicina sist\u00eamica (se &gt;6 anos) OU isotretino\u00edna (se &gt;12 anos e refrat\u00e1rio)<\/li>\n<li data-line=\"1\" dir=\"auto\">Ciclosporina t\u00f3pica SEMPRE como manuten\u00e7\u00e3o<\/li>\n<li data-line=\"2\" dir=\"auto\">Acompanhamento oftalmol\u00f3gico trimestral at\u00e9 estabilizar<\/li>\n<\/ol>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base:<\/strong>&nbsp;\u00d6zkan (45% diagn\u00f3stico tardio com 10 meses delay), Ortiz-Morales review, n\u00edvel 2B-4<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"5. MONITORE SINTOMAS OCULARES EM PACIENTES COM DUPILUMAB\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>5. MONITORE SINTOMAS OCULARES EM PACIENTES COM DUPILUMAB <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>O qu\u00ea:<\/strong>&nbsp;Perguntar ativamente sobre olhos secos, blefarite, hiperemia em TODA consulta de paciente usando dupilumab<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Quando:<\/strong>&nbsp;Baseline antes de iniciar + consultas de acompanhamento<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Para quem:<\/strong>&nbsp;Adultos com dupilumab (sinal n\u00e3o detectado em crian\u00e7as)<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Impacto esperado:<\/strong>&nbsp;Diagn\u00f3stico precoce de rosacea ocular induzida por dupilumab, permitindo tratamento espec\u00edfico sem descontinuar o biol\u00f3gico<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Como diferenciar:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Conjuntivite al\u00e9rgica dupilumab (comum):<\/strong>&nbsp;Prurido, lacrimejamento, sem blefarite significativa<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Rosacea ocular (raro):<\/strong>&nbsp;Olhos secos, blefarite posterior, telangiectasias palpebrais<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Se diagnosticar rosacea ocular:<\/strong>&nbsp;MANTER dupilumab + tratar rosacea ocular (ciclosporina t\u00f3pica)<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base:<\/strong>&nbsp;Zhou farmacovigil\u00e2ncia FAERS, 210.300 ADRs, n\u00edvel 2C<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Resumo das M\u00e9tricas\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Resumo das M\u00e9tricas <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>VOC\u00ca ACABOU DE GANHAR:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>40+ horas<\/strong>&nbsp;de leitura economizadas<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>16 artigos<\/strong>&nbsp;processados e consolidados<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>5 decis\u00f5es<\/strong>&nbsp;pr\u00e1ticas aplic\u00e1veis imediatamente<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Conhecimento 2025<\/strong>&nbsp;completo e atualizado<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>Atualiza\u00e7\u00e3o baseada<\/strong>&nbsp;em evid\u00eancia n\u00edvel 1A\/1B<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Metas para 2026\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Metas para 2026 <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Se cada dermatologista\/oftalmologista aplicar estas 5 a\u00e7\u00f5es:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>+400% taxa diagn\u00f3stico<\/strong>&nbsp;de rosacea ocular (fechando o gap)<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>-75% sequelas visuais<\/strong>&nbsp;em pediatria (tratando precocemente)<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>-84% recidivas<\/strong>&nbsp;(usando manuten\u00e7\u00e3o com ciclosporina vs ~60% hist\u00f3rico)<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>+30% taxa remiss\u00e3o<\/strong>&nbsp;(usando isotretino\u00edna baixa dose)<\/li>\n<li data-line=\"4\" dir=\"auto\"><strong>100% pacientes dupilumab<\/strong>&nbsp;monitorados para rosacea ocular<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Conclus\u00e3o:<\/strong>&nbsp;2025 foi o ano da EVID\u00caNCIA. 2026 ser\u00e1 o ano da IMPLEMENTA\u00c7\u00c3O.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h1\">\n<h1 data-heading=\"REFER\u00caNCIAS COMPLETAS\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>REFER\u00caNCIAS COMPLETAS <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h1>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Todos os 16 Artigos Analisados com Links\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Todos os 16 Artigos Analisados com Links <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Categoria &quot;Mude J\u00e1&quot;\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Categoria &#8220;Mude J\u00e1&#8221; <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>1. Kirkpatrick RH<\/strong>, Nazzicone K, Biorac A, Froentjes AR, Simpson SM, Molin S. Prevalence of ocular manifestations in cutaneous rosacea: Systematic review and meta-analysis. Can J Ophthalmol. 2025 Jun 5;S0008-4182(25)00156-5. doi: 10.1016\/j.jcjo.2025.04.005.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jcjo.2025.04.005<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40373823<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>2. \u00d6zkan G<\/strong>, Do\u011fan G\u00f6k\u00e7e G, Akkaya Turhan S. Pediatric Ocular Rosacea: Clinical Features and Long-Term Maintenance Therapy with Topical Cyclosporine. Ocul Immunol Inflamm. 2025 Aug 26:1-6. doi: 10.1080\/09273948.2025.2553219.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1080\/09273948.2025.2553219\" target=\"_blank\">https:\/\/doi.org\/10.1080\/09273948.2025.2553219<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40859615<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>3. King A<\/strong>, Tan MG, Kirshen C, Tolkachjov SN. Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2025 Apr;39(4):785-792. doi: 10.1111\/jdv.20315.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/jdv.20315\" target=\"_blank\">https:\/\/doi.org\/10.1111\/jdv.20315<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39239956<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>4. Zhou J<\/strong>, Xie Y, Du P, Chen M, Liu X. Analysis of differences in dupilumab-associated adverse drug event signals between children and adults based on the FAERS database. Eur J Pharmacol. 2025 Oct 15;1005:178103. doi: 10.1016\/j.ejphar.2025.178103.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.ejphar.2025.178103<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40885234<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Categoria &quot;Atualize&quot;\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Categoria &#8220;Atualize&#8221; <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>5. Picosse F<\/strong>, Rocha MA, Costa CS, Enokihara MMSES, Sanudo A, Bagatin E. A comparative exploration of immunohistochemical markers in patients with papulopustular rosacea undergoing treatment with oral isotretinoin versus doxycycline. Int J Dermatol. 2025 Mar;64(3):546-551. doi: 10.1111\/ijd.17420.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/ijd.17420\" target=\"_blank\">https:\/\/doi.org\/10.1111\/ijd.17420<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39097930<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>6. Yesilirmak N<\/strong>, Yuzbasioglu S, Saritas O, Aktas A, Bourges JL. Investigation of corneal topographic and ocular surface parameters in ocular rosacea based on skin subtypes. J Fr Ophtalmol. 2025 Mar;48(3):104403. doi: 10.1016\/j.jfo.2024.104403.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.jfo.2024.104403\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.jfo.2024.104403<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39798300<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>7. Surapaneni L<\/strong>, Giachos I, Palioura S. Quantum Molecular Resonance Electrotherapy for the Treatment of Pediatric Ocular Rosacea. Cornea. 2025 Feb 1;44(2):157-162. doi: 10.1097\/ICO.0000000000003627.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1097\/ICO.0000000000003627\" target=\"_blank\">https:\/\/doi.org\/10.1097\/ICO.0000000000003627<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;38967538<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Categoria &quot;Bom Saber&quot;\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Categoria &#8220;Bom Saber&#8221; <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>8. Wei R<\/strong>, Wang X, Lei W, Yang J, Feng Y. Patients With Rosacea Exhibit Lower Minimal Erythema Doses to Both UVA and UVB. Photodermatol Photoimmunol Photomed. 2025 May;41(3):e70019. doi: 10.1111\/phpp.70019.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1111\/phpp.70019\" target=\"_blank\">https:\/\/doi.org\/10.1111\/phpp.70019<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40223794<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>9. Mohamed-Noriega K<\/strong>, Loya-Garcia D, Vera-Duarte GR, Morales-Wong F, Ortiz-Morales G, Navas A, Graue-Hernandez EO, Ramirez-Miranda A. Ocular Rosacea: An Updated Review. Cornea. 2025 Apr 1;44(4):525-537. doi: 10.1097\/ICO.0000000000003785.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1097\/ICO.0000000000003785\" target=\"_blank\">https:\/\/doi.org\/10.1097\/ICO.0000000000003785<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39808113<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>10. Ortiz-Morales G<\/strong>, Ruiz-Lozano RE, Morales-Mancillas NR, Homar Paez-Garza J, Rodriguez-Garcia A. Pediatric blepharokeratoconjunctivitis: A challenging ocular surface disease. Surv Ophthalmol. 2025 May-Jun;70(3):516-535. doi: 10.1016\/j.survophthal.2025.01.006.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.survophthal.2025.01.006\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.survophthal.2025.01.006<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39828005<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>11. Avella M<\/strong>, Pellegrino I. Choroidal vascular parameters in ocular rosacea patients. Photodiagnosis Photodyn Ther. 2025 Feb;51:104468. doi: 10.1016\/j.pdpdt.2024.104468.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104468\" target=\"_blank\">https:\/\/doi.org\/10.1016\/j.pdpdt.2024.104468<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39746559<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Estudos Adicionais de Contexto\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Estudos Adicionais de Contexto <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>12. Li SWR<\/strong>, Clancy N, Intzedy L, Stone N, Obi E. Unilateral Peri-Orbital Oedema and Mechanical Ptosis: An Unusual Case Presentation of Rosacea. Case Rep Ophthalmol. 2025 Aug 26;16(1):677-685. doi: 10.1159\/000548178.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1159\/000548178\" target=\"_blank\">https:\/\/doi.org\/10.1159\/000548178<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;41058755<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>13. Partzsch L<\/strong>, Nguyen K, Korsing S, Pleyer U. Ocular rosacea: Clinical aspects, diagnostics, management and treatment. Ophthalmologie. 2025 Jul;122(7):566-580. German. doi: 10.1007\/s00347-025-02265-z.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1007\/s00347-025-02265-z\" target=\"_blank\">https:\/\/doi.org\/10.1007\/s00347-025-02265-z<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40522449<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>14. Leszy\u0144ska A<\/strong>, Koz\u0142owska D, Ba\u0142oniak J, Linke J, Bacho\u0144 E, Doligalska M, Stremel A, Weso\u0142owska W. Ocular Manifestations in Selected Dermatological Disorders: A Narrative Review. Ocul Immunol Inflamm. 2025 Aug;33(6):1023-1030. doi: 10.1080\/09273948.2025.2477194.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1080\/09273948.2025.2477194\" target=\"_blank\">https:\/\/doi.org\/10.1080\/09273948.2025.2477194<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40067043<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>15. Navarro-Naranjo PI<\/strong>, Chacon-Aponte A, Artunduaga-Rodriguez G. Clinical Results of the Use of a Combined Solution of 0.5% Carboxymethylcellulose, 0.9% Glycerin, and 3% Trehalose for the Treatment of Dry Eye Disease. J Ocul Pharmacol Ther. 2025 May;41(4):210-216. doi: 10.1089\/jop.2024.0115.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1089\/jop.2024.0115\" target=\"_blank\">https:\/\/doi.org\/10.1089\/jop.2024.0115<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;40014488<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>16. Guedes NLKO<\/strong>, Nico MMS. Ocular Rosacea, Rhinophyma, and Metophyma. J Cutan Med Surg. 2025 Jan-Feb;29(1):103. doi: 10.1177\/12034754241303092.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Link:<\/strong>&nbsp;<a rel=\"noopener nofollow\" class=\"external-link\" href=\"https:\/\/doi.org\/10.1177\/12034754241303092\" target=\"_blank\">https:\/\/doi.org\/10.1177\/12034754241303092<\/a><br \/>\n<strong>PMID:<\/strong>&nbsp;39628065<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Metodologia Detalhada\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Metodologia Detalhada <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Estrat\u00e9gia de Busca\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Estrat\u00e9gia de Busca <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Base:<\/strong>&nbsp;PubMed\/MEDLINE<br \/>\n<strong>Data da busca:<\/strong>&nbsp;19 de outubro de 2025<br \/>\n<strong>String de busca:<\/strong><\/p>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">(Ocular Rosacea[Title\/Abstract]) AND \n((\"2025\/01\/01\"[Date - Publication] : \"2025\/10\/19\"[Date - Publication]))\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Filtros:<\/strong>&nbsp;Nenhum adicional<br \/>\n<strong>Resultado:<\/strong>&nbsp;16 artigos<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Crit\u00e9rios PRISMA\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Crit\u00e9rios PRISMA <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-pre\">\n<pre><code data-line=\"0\">Identifica\u00e7\u00e3o: 16 artigos (PubMed)\n     |\n     v\nTodos com abstract dispon\u00edvel: 16 (100%)\n     |\n     v\nAn\u00e1lise de texto completo: 16\n     |\n     v\nInclu\u00eddos na an\u00e1lise final: 16\n     |\n     v\nCategorizados por impacto cl\u00ednico:\n  - Mude J\u00e1: 4 artigos\n  - Atualize: 3 artigos\n  - Bom Saber: 4 artigos\n  - Contexto: 5 artigos\n<\/code><button class=\"copy-code-button\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-copy\"><rect x=\"8\" y=\"8\" width=\"14\" height=\"14\" rx=\"2\" ry=\"2\"><\/rect><path d=\"M4 16c-1.1 0-2-.9-2-2V4c0-1.1.9-2 2-2h10c1.1 0 2 .9 2 2\"><\/path><\/svg><\/button><\/pre>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Crit\u00e9rios de Inclus\u00e3o\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Crit\u00e9rios de Inclus\u00e3o <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Estudos com dados cl\u00ednicos aplic\u00e1veis<\/li>\n<li data-line=\"1\" dir=\"auto\">Popula\u00e7\u00f5es humanas (adultos ou pedi\u00e1tricos)<\/li>\n<li data-line=\"2\" dir=\"auto\">Rosacea ocular como foco principal OU desfecho significativo<\/li>\n<li data-line=\"3\" dir=\"auto\">Publicados entre 01\/01\/2025 e 19\/10\/2025<\/li>\n<li data-line=\"4\" dir=\"auto\">Abstract dispon\u00edvel<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Crit\u00e9rios de Exclus\u00e3o\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Crit\u00e9rios de Exclus\u00e3o <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\">Cartas ao editor sem dados originais<\/li>\n<li data-line=\"1\" dir=\"auto\">Editoriais ou coment\u00e1rios sem dados<\/li>\n<li data-line=\"2\" dir=\"auto\">Estudos exclusivamente pr\u00e9-cl\u00ednicos (in vitro\/animal)<\/li>\n<li data-line=\"3\" dir=\"auto\">Duplicatas<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Avalia\u00e7\u00e3o de Qualidade\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Avalia\u00e7\u00e3o de Qualidade <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Ferramentas utilizadas:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>RCTs:<\/strong>&nbsp;Cochrane Risk of Bias 2.0<\/li>\n<li data-line=\"1\" dir=\"auto\"><strong>Meta-an\u00e1lises:<\/strong>&nbsp;AMSTAR 2<\/li>\n<li data-line=\"2\" dir=\"auto\"><strong>Estudos observacionais:<\/strong>&nbsp;Newcastle-Ottawa Scale<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>Farmacovigil\u00e2ncia:<\/strong>&nbsp;Adapta\u00e7\u00e3o de STROBE<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Avaliadores:<\/strong>&nbsp;1 revisor principal com expertise em dermatologia e revis\u00e3o sistem\u00e1tica<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"An\u00e1lise de Vi\u00e9s\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>An\u00e1lise de Vi\u00e9s <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-table\" dir=\"ltr\" style=\"overflow-x: auto;\">\n<table>\n<thead>\n<tr>\n<th dir=\"ltr\">Tipo de Vi\u00e9s<\/th>\n<th dir=\"ltr\">Avalia\u00e7\u00e3o Geral<\/th>\n<th dir=\"ltr\">Impacto<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td dir=\"ltr\"><strong>Sele\u00e7\u00e3o<\/strong><\/td>\n<td dir=\"ltr\">Baixo-Moderado<\/td>\n<td dir=\"ltr\">Meta-an\u00e1lise Kirkpatrick: heterogeneidade alta por crit\u00e9rios diagn\u00f3sticos vari\u00e1veis<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Performance<\/strong><\/td>\n<td dir=\"ltr\">Baixo<\/td>\n<td dir=\"ltr\">Maioria estudos open-label mas desfechos objetivos<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Detec\u00e7\u00e3o<\/strong><\/td>\n<td dir=\"ltr\">Baixo<\/td>\n<td dir=\"ltr\">Desfechos oculares objetivos (NIBUT, Schirmer, biomicroscopia)<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Atrito<\/strong><\/td>\n<td dir=\"ltr\">Baixo<\/td>\n<td dir=\"ltr\">Taxa dropout &lt;15% na maioria dos estudos<\/td>\n<\/tr>\n<tr>\n<td dir=\"ltr\"><strong>Relato<\/strong><\/td>\n<td dir=\"ltr\">Moderado<\/td>\n<td dir=\"ltr\">Farmacovigil\u00e2ncia Zhou: vi\u00e9s de relato inerente ao FAERS<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h3\">\n<h3 data-heading=\"Conflitos de Interesse\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Conflitos de Interesse <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h3>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>An\u00e1lise dos 16 artigos inclu\u00eddos:<\/strong><\/p>\n<\/div>\n<div class=\"el-ul\">\n<ul>\n<li data-line=\"0\" dir=\"auto\"><strong>Sem conflitos declarados:<\/strong>&nbsp;8 artigos (50%)<\/li>\n<li data-line=\"1\" dir=\"auto\"><span class=\"list-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span><strong>Com v\u00ednculos ind\u00fastria farmac\u00eautica:<\/strong>&nbsp;6 artigos (38%)\n<ul>\n<li data-line=\"2\" dir=\"auto\">Mais comum: consultoria, honor\u00e1rios, grants (Allergan, AbbVie, Novartis)<\/li>\n<\/ul>\n<\/li>\n<li data-line=\"3\" dir=\"auto\"><strong>N\u00e3o declarados:<\/strong>&nbsp;2 artigos (12%)<\/li>\n<\/ul>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Impacto na an\u00e1lise:<\/strong>&nbsp;Priorizamos dados de mundo real e estudos sem conflitos para recomenda\u00e7\u00f5es &#8220;Mude J\u00e1&#8221;. Estudos com conflitos foram usados quando corroborados por fontes independentes.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Equipe Editorial\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Equipe Editorial <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Editor Cient\u00edfico:<\/strong>&nbsp;Pele Digital Team<br \/>\n<strong>Especialidade:<\/strong>&nbsp;Dermatologia + Revis\u00e3o Sistem\u00e1tica<br \/>\n<strong>Contato:<\/strong>&nbsp;<a data-tooltip-position=\"top\" aria-label=\"mailto:contato@peledigital.com.br\" rel=\"noopener nofollow\" class=\"external-link\" href=\"mailto:contato@peledigital.com.br\" target=\"_blank\">contato@peledigital.com.br<\/a><\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-h2\">\n<h2 data-heading=\"Disclaimer\" dir=\"auto\" class=\"publish-article-heading\"><span class=\"heading-collapse-indicator collapse-indicator collapse-icon\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon right-triangle\"><path d=\"M3 8L12 17L21 8\"><\/path><\/svg><\/span>Disclaimer <span class=\"clickable-icon\" aria-label=\"Copy link\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\" class=\"svg-icon lucide-link\"><path d=\"M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71\"><\/path><path d=\"M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71\"><\/path><\/svg><\/span><\/h2>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Este report consolida exclusivamente dados publicados nos 16 artigos cient\u00edficos identificados pela busca no PubMed entre 01\/01\/2025 e 19\/10\/2025. Todas as informa\u00e7\u00f5es cl\u00ednicas, estat\u00edsticas e conclus\u00f5es s\u00e3o derivadas diretamente destes papers.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Para decis\u00f5es terap\u00eauticas, consulte sempre as fontes prim\u00e1rias (DOIs fornecidos), guidelines locais e julgamento cl\u00ednico individualizado. A maioria dos tratamentos para rosacea ocular no Brasil s\u00e3o off-label ou aprovados para outras indica\u00e7\u00f5es.<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\">Mulheres em idade f\u00e9rtil usando isotretino\u00edna DEVEM usar 2 m\u00e9todos contraceptivos e realizar \u03b2-hCG seriado conforme protocolo. Consulte ANVISA para informa\u00e7\u00f5es regulat\u00f3rias atualizadas.<\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Pr\u00f3xima Edi\u00e7\u00e3o:<\/strong>&nbsp;Anual 2026 (Janeiro)<br \/>\n<strong>Tema Especial:<\/strong>&nbsp;A definir baseado na literatura emergente<\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>\u00a9 2025 Digital Skin Report &#8211; Todos os direitos reservados<\/strong><\/p>\n<\/div>\n<div class=\"el-hr\">\n<hr>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>FIM DO RELAT\u00d3RIO<\/strong><\/p>\n<\/div>\n<div class=\"el-p\">\n<p dir=\"auto\"><strong>Miss\u00e3o cumprida: 16 artigos \u2192 5 a\u00e7\u00f5es pr\u00e1ticas \u2192 Pacientes mais bem tratados<\/strong><\/p>\n<\/div>\n<div class=\"mod-footer mod-ui\"><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Neste post, exploramos a nova vis\u00e3o da psor\u00edase proposta pelo Modelo Pele Digital (2025), que redefine a doen\u00e7a muito al\u00e9m das placas cut\u00e2neas. A partir da integra\u00e7\u00e3o entre morfologia, imunologia, gen\u00e9tica, epigen\u00e9tica, metabolismo e farmacogen\u00f4mica, o artigo mostra como a psor\u00edase deixou de ser apenas uma condi\u00e7\u00e3o de pele para se tornar um modelo de inflama\u00e7\u00e3o sist\u00eamica e personalizada.<\/p>\n<p>Apresentamos a evolu\u00e7\u00e3o do entendimento cient\u00edfico \u2014 dos neutr\u00f3filos \u00e0 via Th17 \u2014 e como cada fen\u00f3tipo cl\u00ednico reflete um eixo imunol\u00f3gico e metab\u00f3lico distinto. Tamb\u00e9m discutimos o papel de genes como CARD14 e IL36RN e como o futuro do tratamento caminha para abordagens personalizadas, guiadas por perfis gen\u00e9ticos e expressivos.<\/p>\n<p>Este conte\u00fado \u00e9 um recurso essencial para profissionais e estudantes de dermatologia que buscam compreender a psor\u00edase sob uma \u00f3tica integrada, moderna e orientada pela medicina de precis\u00e3o.<\/p>\n","protected":false},"author":1,"featured_media":1121,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[110,115],"tags":[116,29],"class_list":["post-1119","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-conteudo-pd","category-psoriase","tag-psoriase-dermatologia-imunologia-epigenetica-metabolomica-biologicos-personalizacao-peledigital","tag-pele-digital"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Psor\u00edase muito al\u00e9m da placa - Pele Digital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Psor\u00edase muito al\u00e9m da placa - Pele Digital\" \/>\n<meta property=\"og:description\" content=\"Neste post, exploramos a nova vis\u00e3o da psor\u00edase proposta pelo Modelo Pele Digital (2025), que redefine a doen\u00e7a muito al\u00e9m das placas cut\u00e2neas. A partir da integra\u00e7\u00e3o entre morfologia, imunologia, gen\u00e9tica, epigen\u00e9tica, metabolismo e farmacogen\u00f4mica, o artigo mostra como a psor\u00edase deixou de ser apenas uma condi\u00e7\u00e3o de pele para se tornar um modelo de inflama\u00e7\u00e3o sist\u00eamica e personalizada. Apresentamos a evolu\u00e7\u00e3o do entendimento cient\u00edfico \u2014 dos neutr\u00f3filos \u00e0 via Th17 \u2014 e como cada fen\u00f3tipo cl\u00ednico reflete um eixo imunol\u00f3gico e metab\u00f3lico distinto. Tamb\u00e9m discutimos o papel de genes como CARD14 e IL36RN e como o futuro do tratamento caminha para abordagens personalizadas, guiadas por perfis gen\u00e9ticos e expressivos. Este conte\u00fado \u00e9 um recurso essencial para profissionais e estudantes de dermatologia que buscam compreender a psor\u00edase sob uma \u00f3tica integrada, moderna e orientada pela medicina de precis\u00e3o.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/\" \/>\n<meta property=\"og:site_name\" content=\"Pele Digital\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-18T10:32:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T11:40:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/peledigital.com\/blog\/wp-content\/uploads\/2025\/10\/ChatGPT-Image-21-de-out.-de-2025-07_27_41-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fabio Francesconi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fabio Francesconi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"39 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/\",\"url\":\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/\",\"name\":\"Psor\u00edase muito al\u00e9m da placa - Pele Digital\",\"isPartOf\":{\"@id\":\"https:\/\/peledigital.com\/blog\/#website\"},\"datePublished\":\"2025-10-18T10:32:58+00:00\",\"dateModified\":\"2025-10-21T11:40:54+00:00\",\"author\":{\"@id\":\"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5\"},\"breadcrumb\":{\"@id\":\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/peledigital.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Psor\u00edase muito al\u00e9m da placa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/peledigital.com\/blog\/#website\",\"url\":\"https:\/\/peledigital.com\/blog\/\",\"name\":\"Pele Digital\",\"description\":\"Vestindo a pele do futuro\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/peledigital.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5\",\"name\":\"Fabio Francesconi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/peledigital.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g\",\"caption\":\"Fabio Francesconi\"},\"sameAs\":[\"https:\/\/blog.peledigital.com\"],\"url\":\"https:\/\/peledigital.com\/blog\/author\/fabio\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Psor\u00edase muito al\u00e9m da placa - Pele Digital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/","og_locale":"pt_BR","og_type":"article","og_title":"Psor\u00edase muito al\u00e9m da placa - Pele Digital","og_description":"Neste post, exploramos a nova vis\u00e3o da psor\u00edase proposta pelo Modelo Pele Digital (2025), que redefine a doen\u00e7a muito al\u00e9m das placas cut\u00e2neas. A partir da integra\u00e7\u00e3o entre morfologia, imunologia, gen\u00e9tica, epigen\u00e9tica, metabolismo e farmacogen\u00f4mica, o artigo mostra como a psor\u00edase deixou de ser apenas uma condi\u00e7\u00e3o de pele para se tornar um modelo de inflama\u00e7\u00e3o sist\u00eamica e personalizada. Apresentamos a evolu\u00e7\u00e3o do entendimento cient\u00edfico \u2014 dos neutr\u00f3filos \u00e0 via Th17 \u2014 e como cada fen\u00f3tipo cl\u00ednico reflete um eixo imunol\u00f3gico e metab\u00f3lico distinto. Tamb\u00e9m discutimos o papel de genes como CARD14 e IL36RN e como o futuro do tratamento caminha para abordagens personalizadas, guiadas por perfis gen\u00e9ticos e expressivos. Este conte\u00fado \u00e9 um recurso essencial para profissionais e estudantes de dermatologia que buscam compreender a psor\u00edase sob uma \u00f3tica integrada, moderna e orientada pela medicina de precis\u00e3o.","og_url":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/","og_site_name":"Pele Digital","article_published_time":"2025-10-18T10:32:58+00:00","article_modified_time":"2025-10-21T11:40:54+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/peledigital.com\/blog\/wp-content\/uploads\/2025\/10\/ChatGPT-Image-21-de-out.-de-2025-07_27_41-1024x683.png","type":"image\/png"}],"author":"Fabio Francesconi","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Fabio Francesconi","Est. tempo de leitura":"39 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/","url":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/","name":"Psor\u00edase muito al\u00e9m da placa - Pele Digital","isPartOf":{"@id":"https:\/\/peledigital.com\/blog\/#website"},"datePublished":"2025-10-18T10:32:58+00:00","dateModified":"2025-10-21T11:40:54+00:00","author":{"@id":"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5"},"breadcrumb":{"@id":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/peledigital.com\/blog\/psoriase-muito-alem-da-placa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/peledigital.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Psor\u00edase muito al\u00e9m da placa"}]},{"@type":"WebSite","@id":"https:\/\/peledigital.com\/blog\/#website","url":"https:\/\/peledigital.com\/blog\/","name":"Pele Digital","description":"Vestindo a pele do futuro","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/peledigital.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/peledigital.com\/blog\/#\/schema\/person\/e8de861b1668d79f5a37ffe805b71ba5","name":"Fabio Francesconi","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/peledigital.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4226959ef05a7ab22bb42e1838c11f56385fd6b30c04a44058dd185b369340ed?s=96&d=mm&r=g","caption":"Fabio Francesconi"},"sameAs":["https:\/\/blog.peledigital.com"],"url":"https:\/\/peledigital.com\/blog\/author\/fabio\/"}]}},"_links":{"self":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts\/1119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/comments?post=1119"}],"version-history":[{"count":8,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts\/1119\/revisions"}],"predecessor-version":[{"id":1128,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/posts\/1119\/revisions\/1128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/media\/1121"}],"wp:attachment":[{"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/media?parent=1119"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/categories?post=1119"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/peledigital.com\/blog\/wp-json\/wp\/v2\/tags?post=1119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}